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ABSTRACT 
 
Drue Webb: Development of Improved Dengue 2 Antigen Configurations for a Venezuelan 
Equine Encephalitis Virus Replicon Particle-Launched Dengue Vaccine 
(Under the direction of Laura White) 
 
Dengue has become one of the most important vector-borne diseases.  There is currently no 
licensed dengue vaccine.  The envelope glycoprotein is the major target of neutralizing 
antibodies.  Researchers have tried to identify the most antigenic configuration of the 
envelope protein in different vaccine platforms.  In this study, six dengue 2 E configurations, 
including full-length E, truncated forms of E and the domain III subunit, were expressed as 
antigen using the Venezuelan equine encephalitis virus replicon paricle system and 
characterized in vitro and in vivo.  Each construct was immunogenic in mice; however, there 
was a correlation between protein secretion and neutralizing responses.  Two truncated and 
soluble configurations of E encoding amino acid changes from the previously evaluated 
DEN2 prME-VRP sequence elicited significant neutralizing immune responses.  These 
amino acid changes may be important in the structure of neutralizing epitopes or for proper 
folding, processing and secretion, leading to improved neutralizing antibody responses.   
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CHAPTER I 
 INTRODUCTION 
 
Dengue viruses are members of the Flaviviridae family.  They are enveloped, single-
stranded, positive sense RNA viruses.  The viral genome is packaged inside an isometric 
nucleocapsid, which is surrounded by a lipid bilayer.  The virus is approximately 500 
angstroms in diameter.  Humans are the major natural host of dengue viruses.  The virus is 
transmitted primarily in urban epidemic/endemic cycles by the mosquito vector Aedes 
aegypti. 
 
Epidemiology and Disease 
Dengue has become one of the most important vector-borne viral diseases and a 
serious health risk world wide.  Approximately one-fifth of the world’s population, 2.5 
billion people, is currently at risk for dengue infection.  Areas at greatest risk include urban 
and suburban areas in the tropics and subtropics, mainly the Americas, South-east Asia, the 
Western Pacific, and the Eastern Mediterranean.  Rural areas in Africa are also at risk.  The 
World Health Organization estimates that 50-100 million cases occur annually[1].  Dengue 
infection can result in a range of illnesses, from dengue fever to dengue hemorrhagic fever 
(DHF) and dengue shock syndrome (DSS).  Dengue fever is a self-limiting febrile illness 
with symptoms including mild to high fever, severe headaches, arthralgia, rash and retro-
orbital pain.  It normally does not result in death.  DHF is a more severe illness that involves 
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thrombocytopenia, hemorrhagic tendencies and plasma leakage and can be fatal.  DSS is 
another form of severe illness with symptoms of circulatory failure, low pulse pressure and 
hypotension in addition to all the symptoms exhibited in DHF.  Of the estimated annual 
dengue infections, as many as 500,000 are DHF cases, and up to 20,000 cases are fatal[1].  
There are four antigenically related dengue viruses: dengue 1, dengue 2, dengue 3 and 
dengue 4.  These four serotypes are thought to play an important role in the development of 
more severe illnesses.  Epidemiological studies have shown a correlation between secondary 
dengue infection and development of DHF/DSS[2, 3].  The dominant theory in the field is 
that while infection with one dengue serotype provides life-long protection against a 
homologous secondary infection, it only confers short term protection against heterologous 
infection.  In the long term, low neutralizing antibody titers or cross-reactive, non-
neutralizing antibodies against the other serotypes may enhance a heterologous secondary 
infection.  Results from earlier in vitro and in vivo studies support this theory, referred to as 
antibody dependent enhancement (ADE).  When dengue viruses were combined with sub-
neutralizing levels of antibody, in vitro infection was enhanced compared to infection 
without antibody present[4-7].  This was also shown in rhesus monkeys by injecting dengue-
immune human cord-blood serum intravenously prior to infection with dengue 2 virus, 
resulting in higher viremia compared to monkeys that received normal cord-blood serum[8].  
Results from a more recent study also provide evidence that increased viral titers were 
observed in juvenile rhesus monkeys with a range of subneutralizing antibody titers[7].  
Kontny et al. Made the observation that interferon-gamma further enhances dengue infection 
in the presence of antibody in correlation with an increase in IgG FC receptors (FCγRI), 
suggesting that FCγRI may act as an ADE mediator[9].  The same group published results 
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showing that FCγRII also mediates enhancement in dengue infection in the erythroleukemia 
cell line K562, which expresses FCγRII[10].  This process of enhanced infection via ADE 
might explain the increased risk of severe disease in populations in developing sub-tropical 
and tropical areas where all four serotypes are prevalent, and the chances of second infection 
with heterologous serotypes are high.   
Cases of DHF/DSS are reported with primary infections as well[11, 12].  A 
significant portion of these cases occur in infants, which make up five percent of all cases of 
DHF/DSS[13].  Five percent of children hospitalized with DHF in Asia are infants younger 
than one year old[14], which has been attributed to dropping levels of maternal antibodies 
after birth[15, 16].  Maternal antibodies are transferred through the placenta during 
pregnancy.  Therefore, infants born to dengue-immune mothers receive anti-dengue 
antibodies.  Placentally-transferred immunity remains at protective levels for approximately 
three months, but protective titers have been detected as late as nine months after birth[16, 
17].  During this period of antibody decline, infants are at the greatest risk for dengue 
infection and possible development of DHF/DSS[15].   
Other theories for the pathogenesis of severe dengue infections have been proposed 
that suggest a role for the adaptive and innate immune responses in dengue 
immunopathogenesis.  These include the involvement of complement in mediating dengue 
infection enhancement and a possible role for apoptosis in vascular leakage[6, 18].  There is 
evidence suggesting that T cell activation may also play a role in severe dengue 
pathogenesis.  Secondary infection with a different serotype results in profound activation of 
T cells with a higher affinity for the serotype of the previous infection[19], which is thought 
to explain the delay in viral suppression that results in severe illness.  Although these 
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mechanisms may play a role in severe dengue pathogenesis, the evidence for ADE has been 
one of the largest concerns in vaccine development.  The role of pre-existing immunity, not 
only in lack of protection but also in pathogenesis of DHF, represents an immense challenge 
for dengue vaccine development.   
 
Protein Processing and Viral Structure 
The viral genome is 11 kilobases in length.  The positive sense, single-stranded RNA 
has a single open-reading frame, which is translated into a single polyprotein that is co- and 
post-translationally cleaved by host and viral proteases[20].  The amino-terminus of the 
polyprotein encodes three structural proteins: capsid, the precursor for membrane protein 
(prM), and envelope (E).  prM is cleaved during maturation resulting in membrane (M).  The 
remainder of the polyprotein encodes seven non-structural proteins that are important for 
viral RNA replication and processing.  A hydrophobic signal sequence at the carboxy-
terminus of the capsid protein and two transmembrane domains in prM, including a stop 
transfer sequence and a signal sequence, allow prM and E to be translocated across the 
endoplasmic reticulum (ER) membrane during translation while anchored to the ER 
membrane.  Once co-translational cleavage occurs between capsid, prM, E, and the non-
structural proteins, the capsid protein remains in the cytosol and associates with the viral 
RNA genome and the ER membrane in the cytoplasm.  Each of the membrane proteins, prM 
and E, remain anchored in the ER membrane through their carboxy-terminal transmembrane 
domains, with their ectodomains forming stable heterodimers on the luminal side of the ER.  
Studies with Japanese encephalitis virus (JEV) and tick-borne encephalitis virus (TBE) have 
shown that prM may act as a chaperone during translation and processing, assuring proper 
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folding of E and maturation of the virion[21, 22].  Viral particles bud into the lumen of the 
ER, which provides a host derived lipid bilayer, resulting in immature virions.  Budding of 
empty particles can occur when prM and E are expressed in mammalian cells in the absence 
of other viral proteins[23].  The outer layer of immature virions consists of 60 surface spikes, 
which contain trimers of the prM and E heterodimers.  The presence of spikes causes the 
external diameter to be slightly larger than mature virions.  The fusion peptide of E is 
covered by the three prM proteins of the spike.  It is thought that this association of prM with 
E during particle trafficking protects E in the acidic vesicles of the exocytic pathway from 
premature fusion[24].  The immature virions are trafficked through the trans-Golgi network, 
during which cleavage of prM by furin-like host protease results in maturation of the 
particles into infectious virions released by exocytosis. 
Much of what is known about flavivirus E structure stems from structural analysis of 
the tick-borne encephalitis virus E glycoprotein[25-27].  More recent crystal structures and 
cryo-electron microscopy studies have provided more detailed structure analysis of the 
dengue E protein[28-32].  The E glycoprotein consists of the ectodomain and a stem-anchor 
region.  The ectodomain includes domains I, II, and III (Figure I.2).  Domain I is encoded at 
the amino-terminus of E.  It is located at the center of the monomer structure.  Domain II is 
known as the fusion/dimerization domain and contains the fusion loop, a hydrophobic 
peptide involved in fusion of the virion membrane to cellular membranes.  Domain III folds 
into an IgG-like domain and has been identified as the putative receptor-binding domain[31-
33].  The stem region includes two consecutive amphipathic helices, designated E-H1 and E-
H2, flanking a highly conserved sequence[30].  These helices connect the ectodomain and 
the transmembrane region that anchors the protein to the ER membrane.  They are arranged 
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so that the hydrophobic sides of the helices associate with the hydrophobic residues of the 
membrane[30].  The transmembrane region consists of two antiparallel alpha-helices that are 
embedded in the ER membrane[30].  Two monomers assemble head to tail to form the 
homodimers present on mature virions.  Three sets of immers, referred to as “rafts”, 
arrange in a nearly parallel manner, resulting in a herringbone configuration on the surface of 
the virion[34].  This arrangement results in a mostly smooth viral surface covered with 30 
“rafts”, with the exception of domain III.  The protrusion of domain III from the viral surface 
may aide in receptor binding[35]. 
 
Current Vaccine Strategies 
Despite many decades of research directed towards the development of a dengue 
vaccine, there is still no licensed vaccine.  Earlier replication competent vaccine candidates 
for dengue have been attenuated by serial passage[36-39] or genetic engineering[40].  These 
vaccine designs were based on the success of the live-attenuated yellow fever (YF) 17D 
vaccine[41, 42].  Several groups of researchers continue to focus on developing live-
attenuated vaccines by formulating tetravalent designs[43-45] to induce simultaneous 
immune responses to the four serotypes.  There are a number of live-attenuated dengue 
vaccine candidates that have entered phase I clinical trials.  While some candidates were 
considered safe for further testing[37, 44, 46], others were reactogenic in human volunteers 
and did not induce balanced responses to all four serotypes[47-50].  Other live-attenuated 
vaccine candidates involve chimeric dengue viruses[51-54] or chimeric designs encoding 
dengue structural proteins in the backbone of other flaviviruses[55-61].  Some of these 
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chimeric vaccine designs have entered phase I clinical trials as well, exhibiting low 
reactogenicity and detectable immune responses in human volunteers[54, 58].   
Due to difficulty of tetravalent formulations of live-attenuated viruses to induce 
simultaneous immune responses against all four serotypes after a single dose, other gene-
based vaccine platforms are being evaluated as second generation candidates.  They include 
DNA vectors[62-67], recombinant protein, including subunit designs, expressed from 
bacteria[68, 69], yeast[70, 71] or baculovirus[72-74], and viral vectored vaccines expressing 
recombinant or subunit proteins[75-78] .  These gene-based platform studies have evaluated 
different combinations and configurations of the structural proteins as antigen.  C.-J. Lai et 
al. Have experimented with expressing several recombinant dengue immunogen 
configurations from vaccinia viral vectors[76, 79-83].  Initial results showed that expression 
of E alone or concomitantly with other structural and non-structural proteins from vaccinia 
provided some, if not complete, protection against lethal challenge in mice[79, 82, 83].  
These results suggest it is not necessary to express more than the prM and E glycoprotein to 
induce protective immune responses, allowing for the possibility of smaller immunogens in 
recombinant vaccine designs.   
Several groups examined at immunogenicity and protection elicited by expression of 
full-length prM and E from chimeric flavivirus particles[51, 55, 84], DNA vectors[64, 66, 
85], or viral vectors[75, 83].  Konishi et al. Have shown that expression of prM and E in a 
tetravalent, DNA-based dengue vaccine results in the induction of a long lasting antibody 
response in mice, with neutralizing antibody titers that are low, but detectable[66].  Monkeys 
immunized with prM and E expressed from a DNA plasmid or from chimeric particles 
produced detectable levels of neutralizing antibody and were partially or completely 
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protected against lethal challenge[60, 85, 86].  Co-expression of prM with chimeric or 
truncated forms of E has been examined to determine if modifications to E would improve 
immune responses compared to expression of full-length E with prM.  Chang et al. Expressed 
prM with truncated dengue 2 E and replaced the deleted dengue sequences with the 
corresponding sequences of the JEV E[87].  In this study, chimeric E behaves more like full-
length E with a transmembrane domain.  Immunized mice had detectable virus neutralization 
titers and were protected against lethal dengue challenge.  A DNA vaccine design expressing 
prM and 92% of the amino acid sequence of the dengue 2 E from the amino-terminus 
induced antibodies in mice, including detectable neutralization titers, but did not provide 
protection against lethal challenge[67]. 
Although these studies have shown some level of immune induction from modified E 
expressed with prM, immune responses observed in other studies towards C-terminally 
truncated E without expression of prM have been more protective and in many cases induce 
higher neutralizing responses.  A comprehensive panel of C-terminally truncated E proteins 
expressed from vaccinia virus showed that expression of 79-81% of the amino acid sequence 
of E resulted in soluble protein that was detected in the intracellular and extracellular 
fractions[76].  These conformations were the only truncated antigens that induced detectable 
antibody levels in mice and provided equivalent or better protection in comparison to the 
longer E proteins[76].  Other studies have supported this data, showing that expression of 
truncated E proteins (80-85%) results in antibody induction, low but detectable neutralizing 
antibody titers, and some or complete protection in mice[70-72, 74, 77].  Similar results have 
also been observed in monkeys[63, 80, 88].  These studies have demonstrated that the 
expression of prM and E or truncated E without prM can induce detectable and protective 
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immune responses in mice and non-human primates, making it an attractive antigen for 
vaccine design. 
Recent results involving domain III of the E glycoprotein have important implications 
for vaccine design.  Studies on antibody binding and epitope mapping showed that some 
neutralizing epitopes mapped to the ~100 amino acid sequence encoding domain III[89-92].  
Recombinant domain III also blocks dengue virus binding to mammalian and insect cells[93, 
94].  These studies suggested that immunizing with domain III may be sufficient to induce 
neutralizing antibodies that block binding and entry by the virus.  Crill et al. Showed that 
monoclonal antibodies that map to domain III are able to block virus binding to mammalian 
cells, providing supporting evidence that domain III contains the receptor-binding motif[95].  
To test this, Simmons et al. Designed plasmid vectors that expressed domain III of E for each 
of the four serotypes fused to the maltose binding protein (MBP) of E. Coli, referred to as 
DEN-(B)/MBP[96, 97].  The MBP was cleaved in order to administer DEN-(B) as a subunit 
vaccine.  Groups of mice immunized with DEN1-, DEN2-, DEN3-, or DEN4-(B) had 
significant serotype-specific antibody titers, with neutralizing antibody titers from PRNT 80-
1024, and 80% of the mice were protected from lethal challenge.  Several groups are now 
expressing domain III from different platforms and evaluating the induction of immune 
responses in vivo[98-105].  Immunization of mice with viral vectors such as adenovirus and 
tobacco mosaic virus (TMV) encoding domain III resulted in antibody induction and low but 
detectable neutralizing antibody titers, suggesting that expression of only domain III induced 
immune responses comparable to immune responses elicited by truncated or full-length 
E[100, 106].  Zhang et al. Showed that domain III expressed from E. Coli, purified and 
administered to mice induced low but detectable neutralizing antibody titers and provided 
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complete protection against lethal challenge[99].  Serotype-specific neutralizing antibodies 
were detected in mice immunized with domain III expressed from the pediatric live-
attenuated Schwarz measles vaccine, which supports previous reports that domain III 
contains more serotype-specific epitopes[105].  These studies have demonstrated neutralizing 
immune responses and protection in response to domain III immunization in mice, but they 
were unable to induce neutralizing antibody titers similar to the titers reported by Simmons et 
al[96].   
Although much of the work published is on expression of domain III of a single 
serotype that is purified and administered as a subunit vaccine, some studies have tried 
designing bivalent and tetravalent formulations.  Expression of a bivalent antigen consisting 
of the domain III regions of dengue 2 and 4 connected by a flexible peptide linker in E. Coli 
resulted in specific antibody responses and detectable neutralizing antibodies to the two 
serotypes in mice immunized with purified protein and Freund’s complete adjuvant[102, 
107].  Serotype-specific antibodies and low but detectable neutralizing antibody titers were 
also induced by the individual domain III regions of each of the four serotypes expressed 
from a plasmid, purified and administrated as a tetravalent vaccine in mice[101].  Other 
groups have not seen a very significant immune induction with tetravalent domain III 
expressed from a plasmid, with unbalanced antibody induction and neutralization and 
minimal protection from lethal challenge[104].  These findings support the use of domain III 
of the E glycoprotein as an antigen configuration that induces immune responses in mice and 
monkeys and may minimize cross-reactivity.  Similar studies have been conducted involving 
the domain III of West Nile virus (WNV), and the results show that WNV domain III induces 
virus-specific neutralizing antibodies and elicits protection from lethal challenge in 
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mice[108].  This serotype-specific response is thought to be due to the larger proportion of 
serotype-specific epitopes present in domain III.  Because sub-neutralizing levels of cross-
reactive antibodies may lead to dengue infection enhancement, employing antigens that 
induce lower levels of cross-reactive antibodies while inducing a neutralizing and protective 
serotype-specific response may allow a more effective and safe vaccine design. 
 
Table 1.1 Dengue vaccine candidates. 
Vaccine Candidates Design Stage of Development 
Live, attenuated Vaccines   
WRAIR and GSK[109] Dengue virus Phase I 
Mahidol University 
(Bangkok)[110] 
Dengue virus Preclinical 
NIH, Biologicals E (India), 
Panacea (India)[51, 111] 
Dengue-dengue chimera Phase I 
CDC, Invirage, Shantha 
(India)[51] 
Dengue-dengue chimera Preclinical 
Acambis and Sanofi 
Pasteur[58] 
Dengue-yellow fever chimera Phase II, entering phase III 
Gene-Based Vaccines   
U.S. Navy[62] DNA: DEN E Preclinical 
U.S. Navy[58, 97] Subunit: E DIII Preclinical 
RGP group[112] Viral Vector: adenovirus 
encoding E DII 
Preclinical 
 
Project Rationale 
There is currently no licensed vaccine for dengue.  There are several complications 
associated with vaccine design.  Because a large part of the population in endemic areas has 
previously been infected with at least one of the four serotypes or has maternally-transferred 
anti-dengue antibodies in the case of infants, it is important to use a delivery method that will 
not be inhibited by antibody recognition.  The use of viral vectors and DNA vaccines may 
help to bypass pre-existing antibodies.  These delivery methods are not packaged in dengue 
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structural proteins and are, therefore, not recognized and neutralized by anti-dengue immune 
responses.  However, with viral vectors there may be other complications with pre-existing 
immunity in humans towards the vector of choice, as well as safety issues regarding possible 
recombination.  To avoid the occurrence of antibody dependent enhancement after 
immunization, a vaccine would need to induce a strong and balanced immune response to all 
four serotypes.  If a tetravalent vaccination resulted in a lower antibody titer for any given 
serotype, it might result in severe disease.  It is important that the immune response includes 
a strong induction of neutralizing antibody levels, since non-neutralizing antibodies may also 
result in the development of severe dengue disease. 
Employing a non-propagating Venezuelan equine encephalitis virus (VEE) replicon 
particle (VRP) system as a delivery system provides a way to circumvent the complications 
associated with dengue vaccine development.  The replicon vector encodes a complete 
cDNA copy of the VEE genome in which the VEE structural genes have been replaced with 
a multiple cloning site in the VEE replicon vector downstream of a 26S promoter[113].  
Linearized vector is used to make infectious RNA, capable of replication and transcription, 
which is introduced into cells with two helper RNAs that encode the E1 and E2 glycoproteins 
and the capsid protein downstream of a 26S promoter.  These helper RNAs do not encode the 
nonstructural proteins or cis-acting elements.  Once in the cell, the replicon RNA is packaged 
by the structural proteins translated from the helper RNAs, resulting in VEE replicon 
particles.  By providing the structural elements in trans during packaging, the resulting 
replicon particles are limited to a single round of replication.   
This system provides some solutions to the complications involved in dengue vaccine 
design.  Because the replicon is packaged in the VEE structural proteins, it avoids any 
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blockage by pre-existing dengue immunity, likely to occur with a live dengue virus vaccine.  
Certain strains of VEE replicate in lymphoid tissue and in the context of replicon particles 
the glycoproteins will target lymphoid tissue, delivering antigen directly to antigen 
presenting cells[114-116].  The VEE replicon particles are also capable of high-level 
expression of heterologous genes during a single round of replication[114, 115].  These 
characteristics make the VRP system an effective alternative in vaccine development.  
Several in vivo studies have shown that the VEE replicon particle system is safe in animals, 
including rodents, horses and monkeys[117-119].  A potential HIV vaccine encoding HIV 
Gag expressed from VRP was safe in human volunteers in phase I clinical trials in the U.S. 
and South Africa[120]. 
Our laboratory has shown that expression of the dengue 2 prM and E genes from 
VRPs results in neutralizing antibody responses and protection in mice[121].  The goal of 
this project is to design an optimal immunogen by modifications to the dengue structural 
genes expressed from VRPs.  We have designed five additional constructs expressing 
different truncations of E.  We wanted to test whether truncations at the C-terminus will 
enhance neutralizing immune induction in mice compared to neutralizing immune responses 
induced by full-length E in the presence of prM.  Two truncations were designed to 
determine whether the presence of the H1 domain and the transmembrane domain play a role 
in the immunogenic properties of E.  These constructs encode C-terminally truncated E 
expressing 85% (E85) or 81% (E81) of the amino acid sequence of the protein.  Two other 
constructs encode the same truncated E proteins with specific point mutations.  The E85 
constructs encode the ecotodomain and the H1 domain in the stem region.  The E81 
constructs encode the ectodomain but lack the H1 domain.  The final construct encodes 
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domain III of the E protein (amin acids 296-400).  We hypothesize that E configurations 
expressed both inside and outside of the cell will be more immunogenic in mice, and while 
expressing domain III alone may not provide a stronger immune response than the C-
terminally truncated forms of E containing domains I, II, and III, it may provide a more 
serotype-specific immune response, minimizing cross-reactive antibody induction.  Each 
construct is downstream of the tissue plasminogen activator (tPA) signal sequence to 
promote protein secretion.  Our aim is to characterize these five constructs in comparison to 
the DEN2 prME-VRP construct in vitro and in vivo to determine the best and most practical 
immunogen design for the VRP system. 
CHAPTER II 
MATERIALS AND METHODS 
 
Cells  
BHK-21 cells were obtained from the American Type Culture Collection (ATCC) and 
maintained in alpha minimal essential medium containing 10% tryptose phosphate broth, 
0.29 mg/ml of glutamine and either 10% donor calf serum or 10% fetal calf serum.  Vero-81 
cells were obtained from the ATCC and maintained in D-MEM/F12 medium containing 10% 
fetal calf serum, 0.29 mg/ml of glutamine, non-essential amino acids (1X), penicillin 
(100U/ml) and streptomycin (0.05 mg/ml) and 0.2% sodium bicarbonate. Insect C6/36 cells 
from the ATCC were maintained in alpha minimal essential medium containing 10% fetal 
calf serum. 
Virus 
The mouse-adapted, neurovirulent New Guinea C (NGC) strain of dengue 2 (DEN2) virus 
was provided by the late Robert Shope, UTMB, Galveston, TX.  The stock virus used for 
neutralization assays was propagated in C6/36 cells, titrated on Vero cells and stored at -
80°C at a concentration of 107 PFU/ml.  The WHO reference strains of DEN1, DEN2, DEN3 
and DEN4, provided by Aravinda de Silva, were used for ELISA antigen and were 
propagated in C6/36 cells, concentrated by sedimentation at 72,000 x g for 5 hours through a 
5 ml cushion of 20% (w/v) sucrose dissolved in PBS, and stored at -80°C.   
Antibodies 
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Flavivirus envelope specific 4G2 mouse monoclonal antibody (MAb) was purified from the 
HB-112 hybridoma cell line obtained from the ATCC and concentrated to 0.1mg/ml.  For 
neutralization assays, MAb 4G2 was conjugated to Alexa-Flour 488 (Invitrogen) and was 
used at a concentration of 1mg/ml.  Mouse MAb 3H5-1, specific to DEN2 domain III, was 
obtained from Chemicon International.  Biotinylated anti-mouse IgG (H+L), made in horse, 
was at a concentration of 1.5mg/ml (Vector Laboratories).  Anti-mouse IgG (gamma-chain 
specific)-peroxidase antibody was obtained from Sigma-Aldrich. 
Cloning of dengue envelope immunogens 
Each dengue 2 envelope configuration was cloned into the multiple cloning site of the VEE 
replicon vector, pVR21[122], to generate pVRDEN2prM/E, containing the prM signal 
sequence at the C-terminus of the capsid gene and the prM and  E genes, pVRDEN2E85, 
containing the tPA signal sequence 
(5’ATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGT
CTTCGTTTCG) and amino acids 1-424 of the E gene, which Wahala Wahala helped 
construct, pVRDEN2E81, containing the tpa signal sequence and amino acids 1-397 of the E 
gene, and pVRDEN2EDIII, containing the tpa signal sequence and amino acids 296-400 of 
the E gene.  cDNA of the E genes for prME and E85∆ was amplified from dengue 2 NGC 
strain viral RNA by RT-PCR.  cDNA of the E genes for E81∆ was amplified from isolated 
pVRprME DNA.  The primer sequences were as follows: 
prME forward primer 
(5’AGTCTAGTCCGCCAAGATGTTGAACAGGAGACGCAGAACTGCAGG), prME 
reverse primer (5’GGCGCGCCTTAGGTCTGCACCATAACTCCCAAATACAGCGT), E 
forward primer (5’GAGTCTTCGTTTCGATGCGTTGCATAGGA), E85 reverse primer 
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(5’GGCGCGCCTTAGGATCCAAAATCCCA), E81 reverse primer 
(5’GGCGCGCCTTAAGAACTTCCTTTCTTAAACCAGTTGAGCTTC), 
EDIII forward primer (5’GTCTTCGTTTCGATGTCATACTCTATGTGCAC), 
And EDIII reverse primer (5’GGCGCGCCTTATTGGCCGATAGAACTTCC).  The E genes 
were cloned into the multiple cloning site of pVR21 by further amplification in overlapping 
extension PCR reactions and using the ApaI and AscI sites, upstream and downstream, 
respectively, of the 26S subgenomic RNA transcription start site.  The vectors were 
sequenced to confirm the gene sequence and that no changes occurred in the VEE nsp region, 
the 26S promoter or the 3’UTR.    
VRP packaging 
All pVR21 clones were linearized at a unique NotI site located downstream of the VEE 3’ 
untranslated region and poly(A) sequence.  The mMessage mMachine kit (Ambion) was used 
to generate full-length T7 RNA transcripts as previously described [123].  Two helper T7 
transcripts were generated: one encoding the VEE capsid gene and the other encoding the 
VEE glycoproteins from a cDNA clone of VEE, V3000.  The replicase genes and the cis-
acting packaging signal have been deleted from the helper RNAs.  Each of the pVR 
transcripts (pVRprM/E, pVRE85, pVRE81, pVRDIII, pVREs or pVRE81mut) was mixed 
with the two helper RNAs and were co-transfected into BHK cells by electroporation.  At 22-
24 hours post-electroporation the culture medium was harvested.  Each VRP was safety 
tested for the absence of replication competent virus using a BHK based CPE test, as 
described previously [113, 123]. 
VRP Purification 
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The harvested VRP culture medium was clarified by centrifugation at 12,000 x g for 30 
minutes.  The VRPs were then partially purified and concentrated by sedimentation at 72,000 
x g for 3 hours through a 5 ml cushion of 20% (w/v) sucrose dissolved in PBS.  The pelleted 
VRPs were incubated at 4°C overnight in endotoxin-free PBS with 1% donor calf serum, 
resuspended and stored at -80°C.  VRP titers were determined by IFA.  BHK cells were 
seeded in 8-well chamber slides and infected the next day with serial dilutions of the 
concentrated VRPs.  Infected cells were incubated for 18 hours at 37°C and fixed in 
methanol for 20 minutes at 4°C.  The cells were permeabilized with 0.1% TritonX-100 and 
incubated sequentially with mouse polyclonal anti-VEE nsp antibody, biotinylated anti-
mouse IgG, and avidin conjugated to FITC.  Infectious units (IU) per ml were determined by 
counting replicon-infected fluorescent cells using fluorescent microscopy.   
Site-directed mutagenesis PCR 
Site directed mutagenesis was conducted on pVRE85∆ and pVRE81∆ to change the 
indicated residues to the amino acids present in the pVRprME sequence. Site-specific 
mutations were introduced by using a QuickChange® II Site-Directed Mutagenesis kit, 
following the manufacturers recommended protocol (Stratagene).  Mutagenic primers 25-45 
nucleotides in length were designed for each point mutation.  The sequences of the primers 
are: A33T forward primer (5’GGAAGCTGTGTGACGACGATGGAAAAAACAAACC), 
A33T reverse primer (5’GGTTTGTTTTTTGCCATCGTCGTCACACAGCTTCC), V54A 
and K58E forward primer 
(5’CAGAAGCCAAACAACCTGCCACTCTAAGGGAGTACTGTATAGAGG), V54A and 
K58E reverse primer 
(5’CCTCTATACAGTACTCCCTTAGAGTGGCAGGTTGTTTGGCTTCTG), G112S 
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forward primer (5’GGATTATTTGGAAAAGGAAGCATTGTGACCTGTGCTATG), 
G112S reverse primer (5’CATAGCACAGGTCACAATGCTTCCTTTTCCAAATAATCC), 
N124I forward primer (5’GTTCACATGCAAAAAGATCATGAAAGGAAAAGTCGTGC), 
N124I reverse primer (5’GCACGACTTTTCCTTTCATGATCTTTTTGCATGTGAAC), 
V197A forward primer (5’CGACTTCAATGAGATGGCGTTGCTGCAAATGG), V197A 
reverse primer (5’CCATTTGCAGCAACGCCATCTCATTGAAGTCG). Between 50 and 
75ng of pVRE85∆ or pVRE81∆ template DNA was added to a PCR reaction mixture 
containing 0.2µM of the appropriate sense and antisense primers, 1X Pfu Turbo buffer 
(Stratagene), 0.5mM dNTPs, and 2.5 U of Pfu Turbo (Stratagene).  The PCR reaction 
mixture was then digested with 20 U of DpnI (New England Biolabs) for 3 hours at 37°C to 
eliminate any template DNA.  The cDNA was then precipitated with 40% isopropanol and 
0.2M sodium acetate for 15 minutes at -80°C.  Precipitated cDNA was concentrated at 
14,000rpm for 15 minutes and then washed with 70% ethanol.  The pellet was resuspended in 
2XYT broth and transformed into DH5α chemically competent cells (Invitrogen). 
In vitro VRP infections, radiolabeling, immunoprecipitations, SDS-PAGE 
BHK cells were seeded in 24 well plates.  Monolayers were mock infected or infected the 
next day with the DEN2 prME-, E85∆-, E81∆-, E85-, E81- and DIII-VRP at an MOI of 10.  
Four hours post infection, the media was removed, replaced with methionine and cysteine 
free medium (MP Biomedicals, Inc.), and cells were starved for 1 hour.  The monolayers 
were metabolically radiolabeled with 50-100µCi of [35S] methionine and cysteine/ml (Pro-
Mix, Amersham) for 5 hours.  The media was harvested and clarified at 13,000 rpm for 15 
minutes at 4°C.  Cells were lysed in NP-40 lysis buffer (1X TNE with 0.2% Igepal from 
Sigma and the Complete Mini protease inhibitor cocktail from Roche).  Lysates were 
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clarified at 13,000 rpm for 15 minutes at 4°C.  Envelope proteins were immunoprecipitated 
from the harvested supernatants and cell lysates with MAb 4G2 or MAb 3H5-1 using protein 
A-Sepharose CL-4B beads (Sigma) according to standard protocols.  Immunoprecipitated 
proteins were denatured in 1% SDS containing 50mM 2-β-mercaptoethanol and 
electrophoresed in 12% or 15% SDS-Polyacrylamide gels (SDS-PAGE) with molecular 
weight markers (14.3 to 220 kDa, Amersham).  Radio-labeled and banded proteins were 
visualized using a phosphorimager. 
Indirect Immunofluorescence assay (IFA) for DEN envelope protein 
BHK cells were seeded in eight-well chamber slides.  Monolayers were mock infected or 
infected with DEN2 prME-, E85∆-, E81∆-, E85-, E81- or DIII-VRP at an MOI of 5.  10hpi, 
cells were rinsed with PBS and fixed either in cold methanol for 20 minutes or in 2% 
paraformaldehyde at room temperature for 20 minutes.  Some cells were further 
permeabilized with TBS containing 0.1% TritonX-100 and 0.1% BSA for 15 minutes at 
room temperature.  The cells were stained with the primary DEN2 MAb 3H5-1 (1:400) and 
the secondary biotinylated anti-mouse IgG antibody made in horse (1:1000).  Alexa Fluor® 
594-conjugated streptavidin (1mg/ml, Molecular Probes) was used as the reporter (1:500).  
Stained cells were observed by fluorescent microscopy.  
Immunization of BALB/c mice 
Specific pathogen-free adult (5 weeks old) BALB/c mice were purchased from Charles River 
Laboratories (Wilmington, MA).  Groups of six mice were physically restrained and 
immunized at 6 weeks of age by subcutaneous (s.c.) inoculation in both rear footpads with a 
volume of 10 µl in each footpad.  The mice were observed for 7 days for any adverse 
reactions.  Mice were bled prior to and periodically after immunization by tail vein puncture.  
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Sera was separated and stored at -20°C for later analysis by virus neutralization assays and 
ELISAs.  
Dengue 2 Neutralization Assay 
DEN2 specific neutralizing antibody titers in immunized mouse sera were determined by a 
flow cytometry-based dengue neutralization assay (FRNT) as described earlier[124, 125].  
Briefly, equal volumes of DEN2 NGC virus and heat-inactivated sera diluted two-fold with 
DMEM-F12 containing 1% bovine serum albumin were combined and incubated for 1 hour 
at 37°C.  Vero cells seeded in 24 well plates were infected with the serum/virus mixtures and 
incubated at 37°C.  At 24 hours post infection, the monolayers were trypsanized and washed 
with PBS.  The cells were fixed and permeabilized with Cytofix/Cytoperm (BD-PharMingen, 
San Diego, CA) for 20 minutes at 4°C.  After fixation the cells were washed with Cytowash 
(BD-PharMingen, San Diego, CA), resuspended in 50µl of a 1:600 to 1:1000 dilution of 
ALEXA 488-conjugated monoclonal antibody 4G2 for 1 hour at 4°C, and then washed with 
and resuspended in Cytowash.  Fixed and stained cells were analyzed by flow cytometry 
using a CyAn ADP analyzer (Dako).  Neutralizing antibody titers (F-Neut50) were 
determined based on end-point titers resulting in 50% or more reduction in the number of 
cells positive for dengue infection. 
ELISA for dengue specific IgG 
The antigen used to coat the ELISA plates was purified virus from WHO reference strains of 
dengue 1, 2, 3 and 4 that were propagated in C6/36 cells.  Media were harvested at 7 and 9 
days post-infection, clarified by centrifugation at 12,000 x g for 30 minutes, and concentrated 
by sedimentation at 72,000 x g for 5 hours through a 5 ml cushion of 20% (w/v) sucrose 
dissolved in PBS.  The concentrated viruses were resuspended in PBS and used as antigen.  
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Protein concentrations were determined using the Coomassie Plus-The Better Bradford™ 
Assay Kit (Pierce, Rockford, IL) according to the protocol.  Microtiter 96 well ELISA plates 
were coated with 500µg/well of dengue 1, 2, and 3, 1000µg/well of dengue 4 and an equal 
volume of mock antigen (approximately 10µg) obtained from uninfected C6/36 culture 
medium in carbonate buffer overnight at 4°C.  The wells were thoroughly washed with PBS 
containing 0.05% Tween-20.  Sera collected from immunized mice were serially diluted in 
ELISA wash buffer (PBS and 0.05% Tween-20) containing 10% Sigma Blocking Buffer 
(Sigma), added to the corresponding wells and incubated at 4°C for 2 hours.  After 
thoroughly washing with ELISA wash buffer, HRP-conjugated mouse anti-IgG (1:2000) was 
added to each well.  Antibody bound to antigen was visualized by addition of substrate (equal 
volumes of 0.1 M sodium citrate and 0.1 M citric acid, 2 o-phenylenediamine 
dihydrochloride pellets (Sigma) per 10 ml of substrate and 0.02% hydrogen peroxide).  The 
reaction was stopped after 30 minutes with 0.1 M sodium fluoride and read at 450 nm (single 
wavelength) on automated plate reader.
CHAPTER III 
RESULTS 
 
Design and construction of the DEN2 envelope constructs.   
The design of the different DEN2 E configurations was based on the following 
rationale.  When DEN E protein is co-expressed with prM, they form heterodimers that 
may stay associated with the ER membrane but mostly bud into the lumen of the ER as 
recombinant subviral particles (VLPs)[23].  While in other flaviviruses VLPs are 
efficiently secreted, in the case of DEN these proteins are predominantly found inside the 
cell and may or may not be in the form of VLPs.  One way of increasing the 
immunogenicity of viral membrane proteins that are associated with intracellular 
membranes has been to express them as secreted proteins by removing sequences that 
anchor them to the plasma membrane.  The construct E81 was designed to express the 
ectodomain in the absence of any membrane anchor or membrane associating sequences, 
preceded by a signal sequence for efficient secretion (Figure 3.1).  A second construct, 
E85, was designed to express the ectodomain in the absence of the transmembrane anchor 
sequences but to retain the H1 amphypathic alpha helix (Figure 3.1) that has been 
hypothesized to associate with the hydrophobic residues of the membrane[30].  A third 
construct, EDIII, was designed to express domain III of the ectodomain of E (Figure 3.1), 
to which murine serotype-specific neutralizing MAbs have been mapped and which has 
been shown to elicit a more serotype-specific neutralizing antibody response in vivo
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[97, 101].  The two other constructs characterized in this study, E85∆ and E81∆, were 
intermediate clones that contained amino acid changes with respect to the parental prME 
clone.  Because they showed interesting phenotypes early on, they were further 
characterized. 
 The six DEN2 VRP constructs expressing different configurations of E are 
shown in Figure 3.1.  Each construct contained E structural genes from the DEN2 NGC 
strain.  We had previously constructed a VRP expressing prM and full-length E, referred 
to as DEN2 prME-VRP.  The C-terminal signal sequence of the capsid protein was 
included to promote insertion of prME into the ER membrane during translation.  The 
DEN2 E85-VRP construct encodes 85% of the E amino acid sequence (amino acids 1-
424), which includes the ectodomain and the H1 domain in the stem region.  DEN2 
E85∆-VRP also expresses 85% of the E amino acid sequence, but with three amino acid 
changes with respect to the prME construct: T33A in domain I and D58K and A197V in 
domain II.  The DEN2 E81-VRP expresses 81% of the E amino acid sequence (amino 
acids 1-397), which only includes the ectodomain.  DEN2 E81∆-VRP encodes 81% of 
the E amino acid sequence with four amino acid changes in domain II with respect to 
DEN2 prME-VRP: A54V, S112G, I124N and A197V.  DEN2 DIII-VRP only expresses 
domain III of the envelope glycoprotein (amino acids 296-400).  To ensure efficient 
secretion of the truncated E proteins, a signal sequence from tPA was included at the N-
terminal end in frame with the DEN E sequence.   
Each envelope configuration was inserted into the multiple cloning site of the 
VEE replicon vector, pVR21, downstream of the nonstructural proteins under the control 
of the VEE 26S subgenomic promoter.  Recombinant vectors were sequenced confirming 
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no changes in the VEE non-structural region, 26 S subgenomic region and 3’ untranslated 
region.  Linearized recombinant vector was transcribed in vitro to make infectious RNA 
that was introduced into BHK cells along with two helper RNAs encoding the VEE 
structural proteins, glycoproteins and capsid.  VEE replicon particles secreted into the 
medium were purified, concentrated and titrated.  
 
Expression and secretion of full-length E, truncated E and the DIII subunit in DEN2 
VRPs infected cells.   
The immunogenicity of a viral membrane antigen can be affected by the 
expression levels and secretion efficiency[76].  In vitro studies were conducted to 
compare the full-length and truncated E constructs in their expression and secretion.  E 
protein expression and secretion was evaluated in VRP infected cell monolayers.  BHK 
cells were infected at a high MOI with each of the six DEN2 VRP constructs and 
metabolically radiolabeled with [35S]-methionine and cysteine for 5 to 10 hours post 
infection (hpi).  Harvested cell lysates and supernatants were analyzed for protein 
expression by 15% SDS-PAGE (Figure 3.2A) or proteins immunoprecipitated with 
dengue-specific monoclonal (Figure 3.2B) and anti-dengue polyclonal sera (Figure 3.2C) 
to assess specific expression of E and expression of any associating proteins.   
To compare the levels of E protein synthesized from each construct, total cell 
lysates and concentrated supernatants were analyzed by 15% SDS-PAGE (Figure 3.2A).  
The major radiolabeled protein in each cell lysate migrated at the apparent molecular 
weight for E in its full-length or truncated forms.  A second prominent band migrating at 
the apparent molecular weight of prM was detected in cell lysates infected with DEN2 
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prME-VRP.  A band was not detected at the apparent molecular weight of M after 
cleavage of the pre peptide, suggesting that prM expressed from DEN2 prME-VRP is 
mostly uncleaved.  Because cleavage of prM occurs later in the transport process, it is not 
surprising that prM is mainly detected in the uncleaved form.  However, M is only 8KDa 
and may not be detected in using 12% SDS-PAGE analysis.  Quantitative analysis of the 
density of each E band indicates similar expression levels within approximately 1-fold 
among the DEN2 prME-, E85-, E85∆-, E81 and E81∆-VRP infected cell lysates, 
indicating that truncations to E did not have a significant effect on intracellular 
expression levels.  The band detected in DEN2 prME-VRP infected cell lysates appeared 
less intense, approximately 1.5-fold lower, than the truncated E configurations.  This may 
be due to lower levels of expression from DEN2 prME-VRP but could also be explained 
by lower stability of full-length E co-expressed with prM.  Similar expression levels 
among E85 and E85∆ and among E81 and E81∆ suggest that the amino acid changes did 
not have a significant effect on the expression of truncated E.  In cell lysates infected 
with DEN2 DIII-VRP, a band migrating at the apparent molecular weight of DIII was 
detected with less intensity, at least 3-fold, compared to bands detected for the other 
constructs.  This is most likely due to weaker signal because of the limited number of 
cysteines and methionines in the short, ~100 amino acid sequence rather than lower 
levels of protein expression.  Due to some distortion of the lanes in this particular gel, it 
is difficult to draw any conclusions about protein secretion.   
To confirm identity of the most abundant radiolabeled protein synthesized in 
DEN2 VRP infected cells (Figure 3.2A) as dengue E, DEN-specific protein present in the 
cell lysates and supernatants were immunoprecipitated with MAb (4G2 or 3H5-1) or with 
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mouse anti-DEN2 NGC polyclonal sera.  Analysis of immunoprecipitated proteins by 
12% SDS-PAGE showed DEN-specific E proteins migrating at the predicted apparent 
molecular weight (Figure 3.2B and 2C).  A very prominent band migrating at the 
apparent molecular weight of the E85∆ protein expressed from DEN2 E85∆-VRP was 
observed by immunoprecipitation with MAb (Figure 3.2B) and with polyclonal sera 
(Figure 3.2C).  Since this difference was not apparent in the analysis of total protein 
(Figure 3.2A), it suggests that increased intensity of the E85∆ band is likely due to 
antibody affinity.  Because we did not observe similar increased levels of E85 expressed 
from DEN2 E85-VRP in infected cell lysates by immunoprecipitation (Figure 3.2B and 
2C), it is possible that the amino acid changes in E85∆ resulted in improved antibody 
affinity for E85∆.  Higher levels of secreted E85∆ were detected in supernatants 
immunoprecipitated with MAb compared to supernatants collected from DEN2 E85-VRP 
infected cells (Figure 3.2B).  Similar results were observed in analysis of supernatants 
immunoprecipitated with polyclonal sera, where E85∆ was detected at very low levels 
and E85 was undetectable (Figure 3.2C).  Although these results suggest that the amino 
acid changes in E85∆ promote protein secretion, increased E85∆ in the supernatants may 
also be due to increased protein stability. 
Differences in the levels of E81 and E81∆ immunoprecipitated from infected cell 
lysates were not observed (Figure 3.2B and 2C), suggesting that the amino acid changes 
in E81∆ did not affect antibody affinity.  Differences in secreted protein levels were 
observed in E81 and E81∆ immunoprecipitated from supernatants, similar to the 
differences observed between secreted E85 and E85∆.  Detectable levels of E81∆ were 
observed after immunoprecipitation by MAb (Figure 3.2B) and polyclonal sera (Figure 
 28 
3.2C), while we were unable to detect secreted E81 (Figure 3.2).  As we observed with 
E85 and E85∆, the analysis of total protein suggests that more E81∆ is present in the 
supernatants at the time of harvest compared to E81, and this difference is not due to 
antibody affinity (Figure 3.2A).  Increased E85∆ and E81∆ protein levels in the 
supernatant were also confirmed by precipitation with glycoprotein binding lectin beads 
(data not shown). 
 Although domain III was detected at low levels in the analysis of total protein 
(Figure 3.2A), intense bands migrating at the predicted apparent molecular weight 
(~12KDa) were detected in MAb immunoprecipitated cell lysates and supernatants from 
DEN2 DIII-VRP infected cells (Figure 3.2B), indicating that DIII is expressed 
intracellularly at high levels and efficiently secreted.  Recognition of expressed DIII by 
MAb 3H5-1, which recognizes a conformational epitope in domain III, suggests that the 
protein retains this epitope in its structure.  Bands migrating at the predicted apparent 
molecular weight were detected with very low intensity in cell lysates and supernatants 
immunoprecipitated by anti-DEN2 polyclonal sera.  Epitopes in domain III may not be 
immunodominant in DEN2 NGC immunized mice, resulting in lower levels of antibodies 
that recognize domain III epitopes in mouse polyclonal sera.   
 
Differences in protein secretion and stability detected during expression of DEN2 
VRPs in vitro.   
To examine the kinetics of protein secretion and stability in vitro, pulse-chase 
labeling experiments were conducted where DEN2 VRP infected cells were 
metabolically radiolabeled with [35S]-methionine and cysteine for one hour and chased 
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with excess unlabeled methionine and cysteine for time intervals of 0, 2, 6, 8 or 12 hours 
before harvesting the cell lysates and supernatants.  The lysates and supernatants were 
immunoprecipitated with MAbs 4G2 or 3H5-1 and analyzed by SDS-PAGE (Figure 3.3).  
Strong bands were detected after 0 and 2 hours post chase (hpc) in DEN2 prME-VRP 
infected cell lysates, and protein levels were low to undetectable by 6 hpc.  In the initial 
immunoprecipitation it appeared that lower levels of E were expressed in DEN2 prME-
VRP infected cell lysates compared to expression from the other constructs (Figure 3.2).  
However, the results of the pulse-chase suggest that this difference is due to instability of 
E expressed from DEN2 prME-VRP rather than deficient expression.  E protein was not 
detected at any time point in the supernatants, which suggests that the decrease in cellular 
levels of protein is not due to transport out of the cell.   
E85∆ expressed from DEN2 E85∆-VRP was detected up to 12 hpc in the cell 
lysates.  Levels begin to decrease by 6 hpc, which could be due to secretion more than 
protein instability.  E85 expressed from DEN2 E85-VRP was detected in the cell lysates 
up to 6 hpc and dropped to very low levels by 8 hpc.  At 12 hpc, E85 was no longer 
detectable.  E85 was not detected at any time point in the supernatants.  Therefore, this 
decrease in protein levels in the cell lysates was most likely due to protein instability, 
suggesting that the amino acid changes in E85∆ may confer increased stability to the 
truncated form of E.  Secreted E85∆ was barely detectable at 0 hpc, but peaks at 2 hpc 
and remains relatively stable up to 12 hpc.  These results indicate that the difference in 
E85∆ and E85 secretion is not likely due to degradation of E85 in the supernatants prior 
to harvesting at 10hpi.  Rather, the amino acid changes in E85∆ resulted in increased 
 30 
efficiency of E85∆ secretion.  The mechanism behind this difference remains to be 
elucidated.   
E81∆ expressed from DEN2 E81∆-VRP was detected in the cell lysates up to 8 
hours post-chase and dropped to barely detectable levels by 12 hours post-chase.  Similar 
results were observed in DEN2 E81-VRP infected cell lysates.  However, levels of E81 
were still detected at 12 hours post-chase.  The difference in protein levels at 12 hpc 
indicates that E81 may be slightly more stable.  However, because we detect more E81∆ 
in the supernatants compared to E81, the difference at 12 hpc is most likely due to 
secretion of E81∆ rather than instability of E81∆.  E81∆ secretion from infected cells 
peaked at 2 hpc and gradually decreased.  The delay in secretion of E81∆ is similar to the 
delay observed with secretion of E85∆, suggesting that processing and trafficking of the 
truncated forms of E takes approximately 2 hours.  Secreted E81∆ was detected up to 12 
hpc, indicating the protein remains relatively stable in the media.  Very low levels of E81 
were detected in the supernatants up to 12hpc.  These results indicate that, similar to the 
amino acid changes in E85∆, the amino acid changes in E81∆ result in increased 
efficiency of protein secretion.  
Analysis of DIII immunoprecipitated from cell lysates showed two bands at the 
end of the 1 h pulse.  One band migrated at a higher molecular weight, while the other 
band migrated approximately at the predicted apparent molecular weight of DIII.  The 
larger band may contain the uncleaved tPA signal sequence.  It is thought that the signal 
sequence is cleaved during transport from the ER to the Golgi apparatus.  At early time 
points some of the DIII may still be associated with the tPA signal peptide, which may 
explain the presence of two bands.  The levels of DIII gradually decrease but are still 
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detectable by 12 hpc.  Because high levels of DIII were detected in the supernatants at 
each time point, the decrease in cellular DIII is most likely due to secretion rather than 
instability of DIII.  Detection of DIII in the supernatants up to 12 hpc suggests that DIII 
remains relatively stable.   
 
E85∆ associates with the plasma membrane of infected cells.   
One of the questions we wanted to ask was whether the presence of the H1 
domain in the E85 constructs, which is predicted to interact with the hydrophobic outer 
layer of the ER membrane, facilitates the association of the protein with the plasma 
membrane.  A previous study has shown that including residues of the stem region results 
in E association with the cell membrane [76].  This may affect antigen presentation and 
immunogenicity.  To determine if the E proteins associate with the plasma membrane of 
infected cells, BHK cells infected with DEN2 VRPs were analyzed by IFA (Figure 3.4).  
To visualize intracellular protein, the cells were fixed at 10hpi with either methanol or 
2% PFA and permeabilized with TritonX-100.  Specific staining by MAb 3H5-1 of all six 
configurations was observed, confirming that each construct expresses E protein 
recognized by a conformational MAb (Figure 3.4A).  In order to visualize extracellular 
protein, cells were fixed 10hpi in 2% PFA, in the absence of a permeabilizing agent 
(Figure 3.4B).  This excludes the staining Ab from entering the cell and allows specific 
staining of proteins exposed on the surface of the cell without staining of intracellularly 
localized protein.  Specific staining on the cell surface above background levels was only 
observed in cells infected with DEN2 E85∆-VRP, indicating that E85∆ is not only 
secreted but also associates with the cell membrane.  This may aid in immune induction 
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by increased antigen presentation.  Association with the cellular membranes may also 
promote proper folding.  Although E85 also encodes the H1 domain and would be 
expected to associate with the plasma membrane, inefficient secretion of E85 may 
prevent E85 from reaching the plasma membrane.   
 These results indicate that each construct expresses E protein which is recognized 
by a conformationally dependent monoclonal antibody.  They also show that at 10hpi, 
there are differences in association with the plasma membrane among the six constructs, 
which may be important for immune induction in vivo.  
 
Immunogenicity in mice immunized with DEN2 VRPs.   
To determine the optimal configuration of DEN2 E protein, the antibody 
responses elicited in BALB/c mice immunized with the six DEN2 VRPs were compared.  
For all the experiments, adult BALB/c female mice were immunized by s.c. injection into 
both rear footpads with the indicated VRP configuration.  Serum samples were collected 
at different time points for analysis of antibody induction.  Neutralizing antibody levels 
were evaluated by a flow cytometry-based neutralization assay[124] and total IgG 
production by ELISA. 
 The first immunogenicity study included three groups of six BALB/c female mice 
that were immunized at six weeks of age with a total dose of 5x105 IU of DEN2 prME-, 
E85∆- and E81∆-VRP (Figure 3.5A).  Mice were boosted at 4 weeks post prime (wpp) 
with the same doses.  Serum samples were collected prior to the prime and every two 
weeks post prime and post boost.  All mice had neutralizing antibodies by 2wpp.  By 
4wpp, mice immunized with DEN2 E85∆- and E81∆-VRP had significantly higher 
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neutralizing antibody titers compared to titers in mice immunized with DEN2 prME-VRP 
(P<0.0001) by at least 10-fold.  Boosting mice with DEN2 E85∆- and E81∆-VRP 
resulted in a further 4-fold increase in neutralizing antibody titers by 2 weeks post boost 
(wpb).  An increase in F-Neut50 titers in mice immunized with DEN2 prME also was 
observed.  However, neutralizing antibody titers in DEN2 E85∆- and E81∆-VRP were 
still significantly higher, by at least 16-fold.  These titers remained high at 4wpb. 
 Antibody induction by E85 and E81 compared to prME was evaluated in a similar 
experiment.  Three groups of six BALB/c female mice were immunized at six weeks of 
age with 5x105 IU of DEN2 prME-, E85- and E81-VRP.  Serum samples were collected 
at 2 and 4wpp assayed for neutralizing antibodies.  Similar differences in antibody titers 
to titers observed in mice immunized with DEN2 E85∆- and E81∆-VRP were not 
observed in mice immunized with DEN2 E85- and E81-VRP (Figure 3.5B).  Mice 
immunized with DEN2 prME-VRP had similar mean F-Neut50 titers, compared to the 
previous in vivo studies, at both time points.  DEN2 E85-VRP immunized mice had much 
lower neutralizing antibody titers at 2wpp, 4-fold less than titers induced by prME 
(P=0.0065).  Mean F-Neut50 titers induced by E85 were at or below the limit of detection 
by 4wpp.  A significant decrease in immunogenicity was not observed in mice 
immunized with DEN2 E81-VRP at 2wpp, but by 4wpp neutralizing antibody titers were 
4-fold lower than titers induced by prME.  The difference in neutralizing antibody titers 
showed trends towards significance (P=0.0985).  The decrease in neutralizing antibody 
titers at 4wpp also suggests that the amino acid changes in E85∆ and E81∆ may affect the 
longevity of neutralizing antibody titers.  This would need to be further assessed by 
evaluating titers at later time points.  Evaluating titers post boost for the E85 and E81 
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would also add to the characterization of the truncated configurations in vivo.  These 
results suggest that E85 and E81 were less immunogenic in mice compared to prME, 
which was the converse of results observed in mice immunized with DEN2 E85∆- and 
DEN2 E81∆-VRP.  To further clarify these differences, the truncated E constructs were 
compared in a head-to-head immunogenicity study. 
 Four groups of six BALB/c female mice were immunized at six weeks of age with 
106 IU of DEN2 E85-, E85∆-, E81- and E81∆-VRP.  Serum samples were collected at 2 
and 4 wpp.  This study confirmed the results obtained in the two previous studies.  At 
4wpp, E85∆ and E81∆ induced high mean F-Neut50 titers, similar to those observed in 
the first immunogenicity study (Figure 3.5C).  Similarly, mice immunized with DEN2 
E85- and E81-VRP had significantly lower mean F-Neut50 titers.  The mean F-Neut50 in 
mice immunized with DEN2 E85∆-VRP was at least 12-fold greater than the mean F-
Neut50 induced in mice immunized with DEN2 E85 (P=0.0022).  The mean F-Neut50 
induced in mice immunized with DEN2 E81∆-VRP was at least 20-fold greater than the 
mean F-Neut50 induced in mice immunized with DEN2 E81-VRP (P=0.0043).  These 
results indicate that E85∆ and E81∆ induce significantly greater neutralizing antibody 
titers against DEN2 NGC.  
 The in vivo results indicated that E85∆ and E81∆ were the best antigen 
configurations, in terms of neutralizing antibody induction.  Therefore, a dose response of 
the two antigens was evaluated.  Six groups of three or six BALB/c female mice were 
immunized at six weeks of age with 106, 5x105, or 5x104 IU DEN2 E85∆- or DEN2 
E81∆-VRP, and serum samples were collected at 4wpp.  Although neutralizing antibody 
titers did seem to be dose dependent, a significant decrease in mean F-Neut50 titers did 
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not occur with decreasing doses of DEN2 E85∆-VRP (Figure 3.6A).  Mice immunized 
with 5x104 IU of DEN2 E85∆-VRP had a mean F-Neut50 less than 2-fold lower than mice 
immunized with 106 IU.  A more significant difference was observed in mice immunized 
with DEN2 E81∆-VRP (Figure 3.6B).  The mean F-Neut50 titer in mice immunized with 
106 IU was 2-fold higher than the mean F-Neut50 titer in mice immunized with 5x105 IU.  
The mean F-Neut50 titer in mice immunized with 5x104 IU was at least 14-fold lower 
than the mean F-Neut50 titer in mice immunized 106 IU (P=0.0238) and 5x105 IU 
(P=0.0238), indicating that DEN2 E81∆-VRP immunogenicity is more dependent on 
dose than DEN2 E85∆-VRP immunogenicity and that E85∆ is an effective immunogen 
in mice, even at low doses. 
 In order to evaluate induction of neutralizing antibodies in mice immunized with 
DEN2 DIII in comparison to the response observed in mice immunized with DEN2 
prME-VRP, we immunized groups of four or six BALB/c female mice at six weeks of 
age with 5x105 IU of DEN2 prME-VRP and 106 IU or 5x105 IU of DEN2 DIII-VRP.  
Serum samples were collected at 2 and 4wpp.  Compared to the neutralizing antibody 
titers observed in mice immunized with DEN2 prME-VRP at 2wpp, the mean F-Neut50 
titer in mice immunized with 5x105 IU of DEN2 DIII-VRP was almost 3-fold lower and 
did not increase significantly by 4wpp (Figure 3.7).  Antibody induction was not 
improved with a higher dose.  The mean F-Neut50 titer in mice immunized with 106 IU of 
DEN2 DIII-VRP was lower at 2 and 4wpp than titers observed in mice that received the 
lower dose.  Although the neutralizing antibody titers were lower, the immunogen design 
was able to induce a neutralizing response. 
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 Previous studies expressing dengue E as antigen have shown that different E 
configurations induce high levels of total IgG antibody but fail to induce significant 
levels of neutralizing antibodies[71, 73, 76].  These studies suggest that, in reference to 
total IgG, the proportion of antibody that is capable of neutralizing virus induced by E 
immunogens has historically been low.  To evaluate total IgG antibody titers induced by 
DEN2 VRPs in mice, an ELISA was conducted in which sera collected from mice 
immunized with the six DEN2 VRPs at 4wpp were tested for their ability to bind to 
DEN2.  Each of the six constructs induced anti-DEN2 IgG mean OD=0.2 titers greater 
than log103 (Figure 3.8A).  The highest anti-DEN2 titers were observed in mice 
immunized with DEN2 prME-, DIII- and E81∆-VRP.  To get an idea of what proportion 
of total IgG antibodies were neutralizing, the total IgG DEN2 ELISA titer (log10) was 
plotted on the same axis as the F-Neut50 titer of each mouse at 4wpp converted to log10 
(Figure 3.8B).  Although total IgG titers cannot be compared directly to neutralizing 
antibody titers due to differences in the two assays, it was evident that a greater 
proportion of the antibodies produced by mice immunized with DEN2 E85∆- and E81∆-
VRP were neutralizing compared to antibody proportions in mice immunized with the 
other constructs.  To help evaluate any correlation between total anti-DEN2 IgG and 
neutralizing antibody titers, F-Neut50 titers at 4wpp converted to log10 were plotted 
against the total IgG ELISA titer (log10) against DEN2 (Figure 3.8C).  A line of identity 
where neutralization titers and total ELISA titers have the same value was added to assist 
in the comparison of the relative amount of neutralizing antibody as a proportion of total 
IgG between immunogens.  The data points for the E81∆ and E85∆ immunogens all lie 
much closer to the dotted diagonal line than do the data points for the E81 and E85 
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immunogens or the data points for the prME and DIII immunogens.  This suggests that, 
regardless of the actual quantitative relationship between the sensitivity of the 
neutralization assay versus that of the virus-specific ELISA assay, a much larger 
proportion of the total antibody produced in response to immunization with E81∆ and 
E85∆ has the capacity to neutralize the test DEN2 serotype virus compared to the 
neutralizing response elicited by immunization with any of the other immunogens. 
In order to evaluate cross-reactivity induced by the six VRP constructs, the sera 
collected at 4wpp were also tested for their ability to recognize the other three serotypes: 
DEN1, 3, and 4.  As expected, prME, E85 and E81 VRPs induced cross-reactive IgG 
ELISA titers (Figure 3.8D).  DEN2 prME-VRP induced significantly lower levels of 
cross-reactivity compared to titers induced by E81 (P<0.01), E81∆ (P<0.01) and DIII 
(P<0.01) against DEN1, DEN3 and DEN4.  We did not see any significant changes in 
IgG ELISA titers against the other serotypes between groups immunized with the 
truncated E constructs, suggesting that the amino acid changes did not affect the cross-
reactive antibody response.  It would be important to determine if the amino acid changes 
affected cross-neutralization. 
Based on previous results suggesting that expression of domain III induces a more 
serotype-specific response in mice[96], mice immunized with DEN2 DIII-VRP were 
expected to have lower heterotypic responses compared to the other constructs.  
However, DIII induced high titers of IgG against the four serotypes (Figure 3.8D).  The 
high cross-reactive titers observed in mice immunized with DEN2 DIII-VRP may be due 
to incomplete or improper folding.  High heterotypic responses may also be due to 
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presence of cross-reactive epitopes in DIII or the availability of additional epitopes when 
DIII is expressed out of context of the native E protein.   
 
Figures 
Figure 3.1.  Designs of the six DEN2 E configurations.  Schematic representations of 
the gene cassettes expressing 6 different DEN E configurations, cloned into the multiple 
cloning site of VEE replicon vector pVR21.  Capsid signal sequence (□), pr sequence 
(horizontal stripes), M protein (dark gray), domains I and II of E (light gray), domain III 
of E (gray), TPA signal sequence (diagonal stripes), transmembrane domains (solid black 
bars), changes to the amino acid sequences compared to the E sequence in the DEN2 
prME-VRP construct(*).    
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Figure 3.2.  Expression and secretion of prME, truncated E and DIII subunit from 
DEN2 VRP infected cells.  BHK cells were mock infected or infected at an MOI of 10 
with each of the six DEN2 VRP constructs, starved for 1 hour, and radiolabeled with 
[35S]-methionine and cysteine at 5hpi.  Supernatants and cell lysates were harvested at 
10hpi.  A) The entire cell lysate (CL) and concentrated supernatant (S) were analyzed by 
15% SDS-PAGE.  Molecular weight standards are indicated on the left.  B) The cell 
lysates and supernatants were immunoprecipitated with MAb 4G2, or 3H5-1 for DIII, and 
analyzed by 12% SDS-PAGE.  C) The cell lysates and supernatants were 
immunoprecipitated with pooled polyclonal anti-dengue 2 NGC sera and analyzed by 
12% SDS-PAGE.  The apparent molecular weights of E, prM and DIII are indicated to 
the right of the gel. 
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Figure 3.3.  Protein secretion and stability upon DEN2 VRP infection.  BHK cells 
were mock infected or infected at an MOI of 10 with each of the six VRP constructs, 
starved for 1 hour, radiolabeled with [35S]-methionine and cysteine for 1 hour at 5hpi, and 
chased with excess unlabeled methionine and cysteine.  Cell lysates (CL) and 
supernatants (S) were harvested at several time points (0, 2, 6, 8 and 12 hours of chase).  
Hours of chase are indicated above the lanes.  Harvested CL and S were 
immunoprecipitated with MAb 4G2 or 3H5-1 (DIII).  Immunoprecipitated lysates and 
supernatants were analyzed by 12% SDS-PAGE (15% SDS-PAGE for DIII samples). 
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Figure 3.4.  Expression and cell membrane association of E in DEN2 VRP infected 
cells.  BHK cells were mock infected or infected at an MOI of 5 and fixed at 10hpi.  A)  
Cells were fixed in methanol or 2% PFA (DIII) and permeabilized with 0.1% TritonX-
100.  B) Cells were fixed with 2% PFA without permeabilizing.  Cells were stained with 
MAb 3H5-1 and visualized by fluorescence microscopy.   
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Figure 3.5.  Neutralizing antibody titers induced by truncated E expressed from 
VRP.  A) Three groups of 6 BALB/c female mice were immunized by s.c injection with 
5x105IU of DEN2 prME-, DEN2 E85∆- and DEN2 E81∆-VRP.  10µl was delivered to 
each rear footpad.  The mice were boosted with the same dose at 4wpp.  Mice were bled 
every two weeks from the tail vein.  Sera was separated and tested for neutralizing 
antibody titers by FRNT.  B) 3 groups of 6 BALB/c mice were immunized by s.c. 
injection with 5x105IU of DEN2 prME-, DEN2 E85- and DEN2 E81-VRP.  Volumes 
administered were the same as described above.  Mice were bled at 2 and 4 wpp.  Sera 
was separated and tested for neutralizing antibody titers by FRNT.  The error bars 
represent the standard error mean (SEM).  C) 4 groups of 6 BALB/c mice immunized by 
s.c. infection with 106IU of DEN2 E85∆-, DEN2 E81∆-, DEN2 E85- and DEN2 E81-
VRP.  Volumes and bleeding were as described above.  Sera was separated and tested for 
neutralizing antibody titers by FRNT.  For each group, titers from individual mice are 
shown and the geometric mean is indicated by the black bar. 
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Figure 3.6.  Dose response for DEN2 E85∆- and E81∆-VRP in mice at 4wpp.  Three 
groups of 3 or 6 BALB/c female mice were immunized by s.c. injection in the rear 
footpads with 106, 5x105 and 5x104 IU of DEN2 E85∆-VRP (A) or DEN2 E85∆-VRP 
(B).  10µl was delivered to each rear footpad.  Mice were bled from the tail vein at 4wpp.  
Serum was separated and tested for neutralizing antibody titers by FRNT.  Titers from 
individual mice are shown and the geometric mean is indicated by the black bar. 
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Figure 3.7.  Neutralizing antibody titers induced by domain III.  Three groups of 4 or 
6 BALB/c female mice were immunized by s.c. infection in the rear footpads with 5x105 
IU of DEN2 prME- or DIII-VRP or 106 IU of DEN2 DIII-VRP.  10µl was delivered to 
each rear footpad.  Mice were bled every two weeks from the tail vein.  Serum was 
separated and tested for neutralizing antibody titers by FRNT.  Mean titers and the SEM 
for each group are represented below. 
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Figure 3.8.  Total IgG ELISA titers induced by the DEN2 VRPs.  Sera collected from 
mice immunized with 5x105 IU of DEN2 prME-, E85∆-, E81∆-, E85-, E81- or DIII-VRP 
at 4wpp was tested for total IgG titers against DEN1, 2, 3, and 4.  Plates were coated with 
purified virus.  The signal produced by substrate binding of the secondary goat anti-
mouse-HRP was measured at 450nm.  A sigmoidal dilution curve was fit to the observed 
data points by regression analysis using least squares fit.  The equation describing the 
curve was solved for the y value=0.2.  This x value is considered the OD=0.2 titer.  A) 
The mean total anti-DEN2 IgG antibody titers were ploted as log10.  The error bars 
represent the SEM.  B)  Anti-DEN2 IgG titers converted to log10 of each individual 
mouse was plotted on the same axis as log10 converted F-Neut50 values for each mouse.  
The limit of detection for the neutralizing antibody titers is indicated by a dotted line.  C) 
F-Neut50 titers of individual mice from 4wpp were converted to log10 were plotted 
against total IgG ELISA titers against DEN2 converted to log10 in a scatter plot.  The 
dotted line represents identity between ELISA titers and F-Neut50 titers, where F-Neut50 
titers and ELISA titers have the same value.  D)  Log10 values of the total IgG antibody 
titers (ELISA) against all four serotypes. 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
 
Several characteristics are considered optimal for a dengue vaccine.  In terms of the 
intensity of the antibody response, the ideal vaccine should induce a strong and long lasting 
neutralizing antibody response against each of the four serotypes simultaneously.  In terms of 
the quality of the immune response, the ideal vaccine should induce antibodies that are 
associated with protection and avoid the induction of non-neutralizing antibodies that could 
enhance infection without a strong neutralizing response.  Gene-based dengue vaccine 
research, which has utilized viral vectors, DNA plasmids and subunit proteins, has focused 
on expressing the major dengue surface glycoprotein E, which is the major target of 
protective neutralizing antibodies. One important factor in development of these vaccine 
platforms is to determine the best way to present E to the immune system as well as to 
demonstrate specific configurations or domains of E that are more immunogenic.  This study 
was aimed at answering this question, using the VEE replicon particle vectors as a vaccine 
platform.   
Previous dengue vaccine studies from our laboratory have shown that expression of 
prM and E from VRP results in a rapid induction of a long lasting and significant immune 
response compared to mice immunized with live virus[121]. In order to determine if this 
immune induction could be further improved upon, truncated and subunit forms of E were 
characterized in vitro and in vivo.  The current study provides further characterization of full-
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length E expressed in the presence of prM and provides evidence that some modifications to 
the configuration of the E glycoprotein launched from VRP do not significantly affect 
immunogenicity, while other changes may contribute to better presentation of neutralizing 
epitopes. 
Results from the previous study indicated that full-length E was expressed from 
DEN2 prME-VRP and could be detected in the cell medium after pelleting, most likely on 
the surface of VLPs[121].  The formation of VLPs during expression of full-length E in the 
presence of prM had been previously described for DEN and other flaviviruses[23, 126, 127].  
It has been hypothesized that secretion of VLPs may correlate with immune responses.  In 
the current study, full-length E was not detected in the supernatants of cells infected with the 
prME construct.  However, the supernatants were unconcentrated prior to 
immunoprecipitation, perhaps leading to levels of E below the limit of detection by MAb or 
polyclonal mouse sera.  Most importantly, the results from this study show that full-length E 
expressed with prM is much less stable compared to the other E configurations.  It has been 
shown that improper folding, glycosylation or processing by glycosidases of prM or E results 
in instability of the prM and E heterodimers[128], which may explain the shorter half-life of 
full-length E.  This may also explain the absence of prM or E in the supernatants.  Although 
significant neutralizing titers were detected in DEN2 prME-VRP immunized mice compared 
to titers induced by live virus, these titers were significantly lower than neutralizing titers 
induced by DEN2 E85∆-VRP and DEN2 E81∆-VRP, consistent the observed instability and 
deficiency in secretion.   
Previous characterization of C-terminally truncated E proteins from dengue and 
Japanese encephalitis provided evidence that expression of the ectodomain results in efficient 
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extracellular secretion, while secretion was not observed with E proteins encoding additional 
residues downstream of the ectodomain, responsible for membrane association and 
anchoring[76].  It was hypothesized in these studies that the residues downstream of S397 of 
E may be responsible for directing cellular distribution of E, which prevented export and 
secretion.  It was also indicated that configurations expressing the ectodomain and excluding 
the transmembrane domains were the only E proteins that induced neutralizing antibodies in 
mice.  In the current study, it was thought that employing a strong signal peptide at the N-
terminus of the E sequence would result in efficient secretion of the truncated E 
configurations.  In vitro expression of E85 and E81 revealed that contrary to initial 
predictions, these proteins were secreted at very low or undetectable levels and neither was 
found in association with the plasma membrane.  These truncated forms of E, designed to 
increase secretion (E81) or both secretion and membrane association (E85), did not 
significantly improve the total IgG antibody or the neutralizing antibody responses, 
compared to the response elicited by full-length E in the presence of prM. Rather, these 
constructs elicited reduced neutralizing antibody responses.  
The two intermediate configurations E81∆, with four amino acid changes (A54V, 
S112G, I124N and A197V), and E85∆, with three amino acid changes (T33A, D58K and 
A197V), had more interesting phenotypes.  Compared to their counterparts, these proteins 
appear to have increased intracellular stability and are present at higher levels in the culture 
media as stable secreted forms. While they induce similar levels of total dengue-specific IgG 
antibodies, a higher proportion of those antibodies are able to neutralize DEN2 NGC in vitro.  
Similar neutralizing antibody titers induced by E85∆ and E81∆ and by E85 and E81 suggest 
that presence of the H1 domain does not have a significant affect on neutralizing antibody 
 57 
responses.  However, because the sequences of E85∆ and E81∆ are different, it is difficult to 
draw final conclusions.  It will be important to further evaluate the role of the H1 domain 
once we have determined the residues responsible for the increase in neutralizing antibody 
responses.  The results observed for the truncated E constructs also suggests that there is a 
correlation between increased protein secretion observed in vitro and induction of increased 
mean F-Neut50 titers.  Secretion of antigenic proteins could aide in the presentation of 
neutralizing epitopes, resulting in a more neutralization oriented humoral response.  Antigen 
secretion may also impact memory responses, which would account for the drop in titers 4 
weeks after prime associated with E85 and E81 expression and very low levels of secretion. 
The differences observed in protein secretion during in vitro expression of the 
truncated E constructs indicate that specific point mutations in the ectodomain may result in 
conformational changes that can impact protein export and secretion.  However, the 
mechanism for this is still unknown.  Comparison of the envelope sequences of each of the 
six constructs to the sequence of the DEN2 NGC strain used in the neutralization assays 
indicates that each construct sequence differs from the parental viral sequence.  It has been 
hypothesized that concerted reorganization across the entire surface of the ectodomain is 
likely to occur with any conformational changes[32].  Analysis of the published crystal 
structure of the ectodomain[32] using a molecular visualization system (PyMol) and a protein 
design simulation program (Rosetta design) supports this hypothesis, indicating that these 
amino acid changes may result in significant changes in side chain repacking in several 
regions of the ectodomain.  Although these changes do not necessarily affect binding of 
MAbs used in this study, they may affect other aspects of protein processing and secretion.  
Some of these changes, specifically residues 112 and 124, are within 4 angstroms of residues 
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that are located along the dimer interface, suggesting that dimerization of E may have been 
affected by these residue changes, but this has not been measured directly.  Although the role 
of dimerization in secretion of truncated E proteins has not been fully investigated, it may 
affect secretion efficiency.  Incomplete or inhibited dimerization may prevent complete 
vesicular trafficking or lead to decreased stability in the low pH environment of the vesicles.  
Amino acid 197 is within 4 angstroms of residues located in a hairpin shown to affect the pH 
threshold for membrane fusion[32].  Side-chain reorganization in this region resulting in a 
change in the pH threshold may also have an effect on secretion of the truncated E 
configurations.   
Changes in post-translational modification may also play a role in the different 
secretion phenotypes.  Lorenz et al. observed a dramatic reduction in the secretion of TBE 
soluble E when glycosylation or glucose trimming was inhibited[23].  It has been 
hypothesized that proper glycosylation may affect E homodimer formation.  Although 
glycosylation of the E configurations was not evaluated directly in this study, analysis of 
whether the E configurations are being differentially glycosylated or glucose trimmed would 
be important in determining if post-translational modifications are affecting the secretion of 
soluble E formations. 
Although we have observed a strong correlation between protein secretion and 
neutralizing antibody induction, we also need to take into account possible changes in 
antigenic structure.  Previous studies in which epitopes were mapped by isolating and 
sequencing neutralization escape variants (reviewed in [129]) have determined six 
neutralization regions on the E glycoprotein.  The residue changes in E85∆ and E81∆ involve 
amino acids that have been directly associated with neutralization escape or are within 4 
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angstroms of other amino acids directly involved in neutralization escape.  Analysis of the 
ectodomain by protein modeling programs suggests that the changes in E85∆ and E81∆ 
result in significant side-chain reorganization in these neutralization regions.  Therefore, the 
increase in neutralizing antibody induction may also be due to the enhancement of 
neutralizing epitopes promoted by specific amino acid changes in E85∆ and E81∆.  This is 
supported by the difference in affinity of 4G2 for E85∆ compared to E85.  It is uncertain 
which specific amino acid changes may be responsible for this increase in induction.  
However, the results of this study indicate that changes to the ectodomain sequence can have 
a significant impact on neutralizing antibody induction.  Analysis of viral neutralization of 
different dengue 2 strains will be important to determine if this increase is strain specific.  To 
determine if these changes will affect the induction of a neutralizing response in other 
configurations, the amino acid changes would need to be introduced into the prME sequence 
of full-length E as well as truncated forms.   
It has been proposed for some flaviviruses, including WNV, JEV and DEN, that type-
specific neutralizing antibodies map to E DIII[108, 130-132].  The hypothesis that 
immunizing with DEN DIII results in a type-specific, neutralizing antibody response has 
been tested by Simmons et al. and Mota et al.[96, 101]. In these studies, immunization of 
mice with recombinant DIII as a subunit vaccine elicited serotype-specific antibody 
responses capable of viral neutralization and protection from challenge.  Based on these 
studies, we predicted that expressing domain III in the absence of other DEN2 E sequences 
from VRPs would induce a strong neutralizing antibody response with limited induction of 
cross-reactive, non-neutralizing antibodies.  If this hypothesis were true, a tetravalent 
formulation based on all four DIII antigens expressed from the same VRP would be a 
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promising strategy.  The high levels of intracellular and extracellularly secreted DIII proteins 
detected during in vitro infection with DEN2 DIII-VRP suggested that the configuration may 
induce significant antibody responses in mice, based on the immunogenicity results observed 
for the truncated ∆ configurations.  The anti-DEN2 IgG ELISA titers in mice immunized 
with DEN2 DIII-VRP were as high as or even higher than those detected in mice immunized 
with all other configurations, indicating that the DIII antigen configuration is highly 
immunogenic. However, the neutralizing antibody titers were never higher than the mean F-
Neut50 titers detected in mice immunized with DEN2 prME-VRP, which may be due to 
improper presentation of neutralizing epitopes without the presence of additional E 
sequences or other carrier sequences.   
Levels of cross-reactive IgG to the other three serotypes induced in mice immunized 
with DEN2 DIII-VRP were higher than expected, suggesting that our DIII design 
predominantly presented non-neutralizing epitopes that are common to the other serotypes.  
Sukopolvi et al. have shown that while serotype and subcomplex-specific MAbs map to 
epitopes in domain III, a conserved region in domain III predicted to have limited access in 
the context of the mature virion is recognized by poorly neutralizing and cross-reactive 
antibodies[91].  This study suggests that expression of domain III alone and out of the 
context of the ectodomain may result in not only serotype-specific immune responses, but 
cross-reactive responses as well, due to increased availability to cross-reactive, non-
neutralizing epitopes.  This may account for the high levels of cross-reactive antibodies 
elicited in mice by the DIII configuration. 
The two bands detected at early time points in DEN2 DIII-VRPs infected cell lysates 
during pulse-chase experiments may offer an alternative explanation for the unexpected 
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immunogenicity data.  It was hypothesized that the presence of two bands migrating at 
different molecular weights was due to cleavage of the tPA sequence during transport from 
the ER to the Golgi apparatus.  The predicted molecular weight of the tPA sequence (~2KDa) 
may account for the band migrating at a higher molecular weight.  However, this observation 
may also be explained by partial degradation of domain III that might occur during transport 
from the ER.  Saejung et al. showed that expression of domain III with a hexahistidine tag 
and a signal peptide at the N-terminus from a tobacco mosaic viral (TMV) vector in plants 
resulted in two bands detected by domain III specific monoclonal antibodies[100].  Only the 
band migrating at the higher molecular weight was detected by an anti-His antibody, 
suggesting that cleavage at the C-terminus had occurred during expression.  Most of the 
studies showing serotype-specific antibody responses elicited by immunization with domain 
III involved expression of domain III in association with other proteins[96, 105].  Other 
studies involving expression of domain III alone from other vectors have not evaluated cross-
reactive antibody titers.  One group expressing DIII alone from a plasmid observed serotype-
specific antibody induction in mice[101].  However, a signal peptide was not included at the 
N-terminus to promote retention in the ER membrane and secretion.  These studies suggest 
that expression of domain III with an ER retention signal peptide may result in partial 
degradation at the C-terminus of DIII, which could explain the induction of a more cross-
reactive response elicited by the DIII design and may also explain low levels of neutralizing 
antibodies. 
Modifications to the DIII design may result in improved immune responses elicited in 
mice.  Expression of several DIII sequences from the same serotype separated by flexible 
linkers may allow for expression of a more stable protein similar to its native conformation.  
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This may promote multimerization, which may aide in proper folding and could protect the 
C-terminus or other regions of the domain from any cleavage or degradation.  However, the 
presentation of neutralizing epitopes would need to be verified by detection with several 
monoclonal antibodies mapping to type-specific neutralizing epitopes on domain III.  If 
domain III can be successfully expressed as a multimer, resulting in serotype-specific, 
neutralizing immune responses in vivo, then a tetravalent DIII design may be effectively 
expressed from VRPs. 
This study provided a characterization of several DEN2 E antigenic configurations in 
a VRP-launched vaccine design.  The results show that VRP vectors are capable of 
expressing different configurations of DEN2 E protein at high levels in the cytoplasm, some 
of which are efficiently secreted.  We have identified two constructs with improved 
neutralizing responses, which will aide in antigenic design in future studies.  These results 
provide future directions for evaluating antigenic configurations and to determine the most 
effective immunogen design.  We have gained a better understanding of the in vitro 
characteristics and antigenicity of several E configurations and sequences, providing several 
future directions to further evaluate and optimize dengue envelope expressed from VEE 
replicon particles. 
 63 
REFERENCES 
 
[1] W.H.O. Vector-Borne Viral Infections: Dengue Fever. In, 2008. 
[2] Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, 
et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, 
Thailand. I. The 1980 outbreak. Am J Epidemiol 1984;120(5):653-69. 
[3] Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazques S, et al. 
Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol 
2000;152(9):793-9; discussion 804. 
[4] Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection 
enhancement by non-neutralizing antibody. J Exp Med 1977;146(1):201-17. 
[5] Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate 
leukocytes. Nature 1977;265(5596):739-41. 
[6] Yamanaka A, Kosugi S, Konishi E. Infection-enhancing and -neutralizing activities 
of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by 
complement levels. J Virol 2008;82(2):927-37. 
[7] Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-
mediated enhancement of dengue virus infection in vitro and in vivo and strategies for 
prevention. Proc Natl Acad Sci U S A 2007;104(22):9422-7. 
[8] Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by 
passively transferred antibody. J Infect Dis 1979;140(4):527-33. 
[9] Kontny U, Kurane I, Ennis FA. Gamma interferon augments Fc gamma receptor-
mediated dengue virus infection of human monocytic cells. J Virol 1988;62(11):3928-33. 
[10] Littaua R, Kurane I, Ennis FA. Human IgG Fc receptor II mediates antibody-
dependent enhancement of dengue virus infection. J Immunol 1990;144(8):3183-6. 
[11] Scott RM, Nimmannitya S, Bancroft WH, Mansuwan P. Shock syndrome in primary 
dengue infections. Am J Trop Med Hyg 1976;25(6):866-74. 
 64 
[12] Barnes WJ, Rosen L. Fatal hemorrhagic disease and shock associated with primary 
dengue infection on a Pacific island. Am J Trop Med Hyg 1974;23(3):495-506. 
[13] Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue 
hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 
2002;8(12):1474-9. 
[14] Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, Chambonneau 
L, et al. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally 
transferred dengue neutralizing antibodies in thai children. J Infect Dis 2006;194(11):1570-6. 
[15] Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, Thien NT, et al. Maternal 
antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 
2007;196(3):416-24. 
[16] Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue 
antibodies are important in the development of dengue hemorrhagic fever in infants. Am J 
Trop Med Hyg 1988;38(2):411-9. 
[17] Watanaveeradej V, Endy TP, Samakoses R, Kerdpanich A, Simasathien S, Polprasert 
N, et al. Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop 
Med Hyg 2003;69(2):123-8. 
[18] Limonta D, Capo V, Torres G, Perez AB, Guzman MG. Apoptosis in tissues from 
fatal dengue shock syndrome. J Clin Virol 2007;40(1):50-4. 
[19] Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul 
N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue 
hemorrhagic fever. Nat Med 2003;9(7):921-7. 
[20] Knipe DM, Howley PM, editors. Fields Virology. fourth ed. Philidelphia: Lippincott 
Williams &Wilkins, 2001. 
[21] Lorenz IC, Allison SL, Heinz FX, Helenius A. Folding and dimerization of tick-borne 
encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol 
2002;76(11):5480-91. 
[22] Konishi E, Mason PW. Proper maturation of the Japanese encephalitis virus envelope 
glycoprotein requires cosynthesis with the premembrane protein. J Virol 1993;67(3):1672-5. 
 65 
[23] Lorenz IC, Kartenbeck J, Mezzacasa A, Allison SL, Heinz FX, Helenius A. 
Intracellular assembly and secretion of recombinant subviral particles from tick-borne 
encephalitis virus. J Virol 2003;77(7):4370-82. 
[24] Guirakhoo F, Bolin RA, Roehrig JT. The Murray Valley encephalitis virus prM 
protein confers acid resistance to virus particles and alters the expression of epitopes within 
the R2 domain of E glycoprotein. Virology 1992;191(2):921-31. 
[25] Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from 
tick-borne encephalitis virus at 2 A resolution. Nature 1995;375(6529):291-8. 
[26] Bhardwaj S, Holbrook M, Shope RE, Barrett AD, Watowich SJ. Biophysical 
characterization and vector-specific antagonist activity of domain III of the tick-borne 
flavivirus envelope protein. J Virol 2001;75(8):4002-7. 
[27] Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. Mutational evidence for an 
internal fusion peptide in flavivirus envelope protein E. J Virol 2001;75(9):4268-75. 
[28] Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, et al. Structures of 
immature flavivirus particles. Embo J 2003;22(11):2604-13. 
[29] Rey FA. Dengue virus envelope glycoprotein structure: new insight into its 
interactions during viral entry. Proc Natl Acad Sci U S A 2003;100(12):6899-901. 
[30] Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, Mukhopadhyay S, et al. 
Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. 
Nat Struct Biol 2003;10(11):907-12. 
[31] Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal 
structure of dengue virus type 3 envelope glycoprotein. J Virol 2005;79(2):1223-31. 
[32] Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue 
virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003;100(12):6986-91. 
[33] Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, Baker TS, et al. 
Conformational changes of the flavivirus E glycoprotein. Structure 2004;12(9):1607-18. 
 66 
[34] Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure 
of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 
2002;108(5):717-25. 
[35] Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus 
life cycle. Nat Rev Microbiol 2005;3(1):13-22. 
[36] Hoke CH, Jr., Malinoski FJ, Eckels KH, Scott RM, Dubois DR, Summers PL, et al. 
Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and 
immunogenicity in humans. Am J Trop Med Hyg 1990;43(2):219-26. 
[37] Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, et al. 
A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell 
culture is attenuated and immunogenic for humans. J Infect Dis 1994;170(6):1448-55. 
[38] Eckels KH, Harrison VR, Summers PL, Russell PK. Dengue-2 vaccine: preparation 
from a small-plaque virus clone. Infect Immun 1980;27(1):175-80. 
[39] Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A. 
Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): 
clinical, immunological and biological responses in adult volunteers. Bull World Health 
Organ 1987;65(2):189-95. 
[40] Cahour A, Pletnev A, Vazielle-Falcoz M, Rosen L, Lai CJ. Growth-restricted dengue 
virus mutants containing deletions in the 5' noncoding region of the RNA genome. Virology 
1995;207(1):68-76. 
[41] Dick GW, Gee FL. Immunity to yellow fever nine years after vaccination with 17D 
vaccine. Trans R Soc Trop Med Hyg 1952;46(4):449-58. 
[42] Cannon DA, Dewhurst F, Meers PD. Mass vaccination against yellow fever by 
scarification with 17D strain vaccine. Ann Trop Med Parasitol 1957;51(3):256-63. 
[43] Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, et al. 
Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated 
dengue virus vaccination. J Infect Dis 2006;193(12):1658-65. 
 67 
[44] Rothman AL, Kanesa-thasan N, West K, Janus J, Saluzzo JF, Ennis FA. Induction of 
T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue 
virus vaccine. Vaccine 2001;19(32):4694-9. 
[45] Blaney JE, Jr., Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated 
tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective 
neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 
2005;79(9):5516-28. 
[46] Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al. Phase 
I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med 
Hyg 2003;69(6 Suppl):48-60. 
[47] Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R, et al. Innate 
and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated 
dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006;24(23):4914-26. 
[48] Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, et al. Immunogenicity 
and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy 
Australian adults. Vaccine 2006;24(9):1238-41. 
[49] Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, et al. Safety 
and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human 
volunteers. Vaccine 2001;19(23-24):3179-88. 
[50] Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, et al. 
Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue 
vaccine candidates. Am J Trop Med Hyg 2003;69(6 Suppl):24-31. 
[51] Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. 
Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J 
Virol 2003;77(21):11436-47. 
[52] Bray M, Men R, Lai CJ. Monkeys immunized with intertypic chimeric dengue 
viruses are protected against wild-type virus challenge. J Virol 1996;70(6):4162-6. 
[53] Bray M, Lai CJ. Construction of intertypic chimeric dengue viruses by substitution of 
structural protein genes. Proc Natl Acad Sci U S A 1991;88(22):10342-6. 
 68 
[54] Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE, Jr., Thumar B, et al. 
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, 
immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 
2005;191(5):710-8. 
[55] Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. 
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in 
nonhuman primates. J Virol 2000;74(12):5477-85. 
[56] Pletnev AG, Bray M, Huggins J, Lai CJ. Construction and characterization of 
chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci U S A 
1992;89(21):10532-6. 
[57] Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety 
and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in 
nonhuman primates. J Virol 2004;78(9):4761-75. 
[58] Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live 
attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I 
clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction 
of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 
2006;2(2):60-7. 
[59] Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, et al. 
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-
dengue virus tetravalent vaccine. J Virol 2001;75(16):7290-304. 
[60] Galler R, Marchevsky RS, Caride E, Almeida LF, Yamamura AM, Jabor AV, et al. 
Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for 
rhesus monkeys. Braz J Med Biol Res 2005;38(12):1835-46. 
[61] Chambers TJ, Jiang X, Droll DA, Liang Y, Wold WS, Nickells J. Chimeric Japanese 
encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and 
protection against dengue encephalitis in mice. J Gen Virol 2006;87(Pt 11):3131-40. 
[62] Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, et al. A chimeric 
tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in 
rhesus macaques. Virology 2006;353(1):166-73. 
 69 
[63] Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, et al. 
Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. 
J Gen Virol 2000;81(Pt 7):1659-67. 
[64] Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW. Vaccination of rhesus 
macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-
membrane and envelope genes. Am J Trop Med Hyg 2003;68(4):469-76. 
[65] Ocazionez Jimenez R, Lopes da Fonseca BA. Recombinant plasmid expressing a 
truncated dengue-2 virus E protein without co-expression of prM protein induces partial 
protection in mice. Vaccine 2000;19(6):648-54. 
[66] Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing 
antibody and anamnestic responses to four serotypes in mice. Vaccine 2006;24(12):2200-7. 
[67] Kochel T, Wu SJ, Raviprakash K, Hobart P, Hoffman S, Porter K, et al. Inoculation 
of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. 
Vaccine 1997;15(5):547-52. 
[68] Mason PW, Zugel MU, Semproni AR, Fournier MJ, Mason TL. The antigenic 
structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli. J 
Gen Virol 1990;71 ( Pt 9):2107-14. 
[69] Cohen S, Powell CJ, Dubois DR, Hartman A, Summers PL, Eckels KH. Expression 
of the envelope antigen of dengue virus in vaccine strains of Salmonella. Res Microbiol 
1990;141(7-8):855-8. 
[70] Valdes I, Hermida L, Zulueta A, Martin J, Silva R, Alvarez M, et al. Expression in 
Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein. Mol 
Biotechnol 2007;35(1):23-30. 
[71] Mune M, Rodriguez R, Ramirez R, Soto Y, Sierra B, Rodriguez Roche R, et al. 
Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia 
pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. 
Arch Virol 2003;148(11):2267-73. 
[72] Putnak R, Feighny R, Burrous J, Cochran M, Hackett C, Smith G, et al. Dengue-1 
virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-
neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 
1991;45(2):159-67. 
 70 
[73] Delenda C, Staropoli I, Frenkiel MP, Cabanie L, Deubel V. Analysis of C-terminally 
truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and 
immunogenic properties in mice. J Gen Virol 1994;75 ( Pt 7):1569-78. 
[74] Delenda C, Frenkiel MP, Deubel V. Protective efficacy in mice of a secreted form of 
recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells. 
Arch Virol 1994;139(1-2):197-207. 
[75] Raja NU, Holman DH, Wang D, Raviprakash K, Juompan LY, Deitz SB, et al. 
Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 
antigens from a single complex adenoviral vector. Am J Trop Med Hyg 2007;76(4):743-51. 
[76] Men RH, Bray M, Lai CJ. Carboxy-terminally truncated dengue virus envelope 
glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased 
immunogenicity in mice. J Virol 1991;65(3):1400-7. 
[77] Jaiswal S, Khanna N, Swaminathan S. Replication-defective adenoviral vaccine 
vector for the induction of immune responses to dengue virus type 2. J Virol 
2003;77(23):12907-13. 
[78] Fonseca BA, Pincus S, Shope RE, Paoletti E, Mason PW. Recombinant vaccinia 
viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in 
mice. Vaccine 1994;12(3):279-85. 
[79] Zhao BT, Prince G, Horswood R, Eckels K, Summers P, Chanock R, et al. 
Expression of dengue virus structural proteins and nonstructural protein NS1 by a 
recombinant vaccinia virus. J Virol 1987;61(12):4019-22. 
[80] Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, et al. Immunization 
of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a 
truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 
virus challenge. Vaccine 2000;18(27):3113-22. 
[81] Falgout B, Bray M, Schlesinger JJ, Lai CJ. Immunization of mice with recombinant 
vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against 
lethal dengue virus encephalitis. J Virol 1990;64(9):4356-63. 
[82] Bray M, Zhao BT, Markoff L, Eckels KH, Chanock RM, Lai CJ. Mice immunized 
with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without 
 71 
nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J Virol 
1989;63(6):2853-6. 
[83] Bray M, Lai CJ. Dengue virus premembrane and membrane proteins elicit a 
protective immune response. Virology 1991;185(1):505-8. 
[84] Chen W, Kawano H, Men R, Clark D, Lai CJ. Construction of intertypic chimeric 
dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol 
1995;69(8):5186-90. 
[85] Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, et al. A 
dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides 
protection from viral challenge in Aotus monkeys. Vaccine 2000;18(27):3166-73. 
[86] Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, et al. Viremia 
and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric 
vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type 
dengue virus isolates. Virology 2002;298(1):146-59. 
[87] Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, Roehrig JT, et al. 
Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric 
plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 2003;306(1):170-
80. 
[88] Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An 
evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine 
candidates in the rhesus macaque model. Vaccine 2005;23(35):4442-52. 
[89] Roehrig JT, Johnson AJ, Hunt AR, Bolin RA, Chu MC. Antibodies to dengue 2 virus 
E-glycoprotein synthetic peptides identify antigenic conformation. Virology 
1990;177(2):668-75. 
[90] Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, et al. Use of 
recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous 
antigenic sites on the dengue virus envelope glycoprotein. Virology 1992;187(2):480-91. 
[91] Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, 
et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue 
virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007;81(23):12816-26. 
 72 
[92] Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a 
dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) 
of dengue 2 virus. Virology 2007;366(2):349-60. 
[93] Hung JJ, Hsieh MT, Young MJ, Kao CL, King CC, Chang W. An external loop 
region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific 
binding to mosquito but not mammalian cells. J Virol 2004;78(1):378-88. 
[94] Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue virus 
serotypes 1 and 2 inhibit virus entry. Microbes Infect 2007;9(1):1-6. 
[95] Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus 
E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 
2001;75(16):7769-73. 
[96] Simmons M, Nelson WM, Wu SJ, Hayes CG. Evaluation of the protective efficacy of 
a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in 
mice. Am J Trop Med Hyg 1998;58(5):655-62. 
[97] Simmons M, Murphy GS, Hayes CG. Short report: Antibody responses of mice 
immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med 
Hyg 2001;65(2):159-61. 
[98] Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, Prado I, et al. Amino acid 
changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and 
immunogenicity in mice. Virus Res 2006;121(1):65-73. 
[99] Zhang ZS, Yan YS, Weng YW, Huang HL, Li SQ, He S, et al. High-level expression 
of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing 
antibodies in BALB/C mice. J Virol Methods 2007;143(2):125-31. 
[100] Saejung W, Fujiyama K, Takasaki T, Ito M, Hori K, Malasit P, et al. Production of 
dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine 
2007;25(36):6646-54. 
[101] Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C. Induction of 
protective antibodies against dengue virus by tetravalent DNA immunization of mice with 
domain III of the envelope protein. Vaccine 2005;23(26):3469-76. 
 73 
[102] Khanam S, Etemad B, Khanna N, Swaminathan S. Induction of neutralizing 
antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of 
linked envelope domains III of these two serotypes. Am J Trop Med Hyg 2006;74(2):266-77. 
[103] Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, et al. A recombinant 
fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic 
and protective in nonhuman primates. Vaccine 2006;24(16):3165-71. 
[104] Chen S, Yu M, Jiang T, Deng Y, Qin C, Qin E. Induction of tetravalent protective 
immunity against four dengue serotypes by the tandem domain III of the envelope protein. 
DNA Cell Biol 2007;26(6):361-7. 
[105] Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Fevrier M, et al. 
Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific 
Neutralizing Antibodies to Dengue Virus. PLoS Negl Trop Dis 2007;1(3):e96. 
[106] Khanam S, Khanna N, Swaminathan S. Induction of neutralizing antibodies and T 
cell responses by dengue virus type 2 envelope domain III encoded by plasmid and 
adenoviral vectors. Vaccine 2006;24(42-43):6513-25. 
[107] Khanam S, Rajendra P, Khanna N, Swaminathan S. An adenovirus prime/plasmid 
boost strategy for induction of equipotent immune responses to two dengue virus serotypes. 
BMC Biotechnol 2007;7:10. 
[108] Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, 
Osterhaus AD. Immunization with West Nile virus envelope domain III protects mice against 
lethal infection with homologous and heterologous virus. Vaccine 2008;26(2):153-7. 
[109] Kanesa-Thasan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, et al. 
Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg 2003;69(6 
Suppl):32-8. 
[110] Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety 
and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue 
vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004;23(2):99-109. 
[111] Blaney JE, Jr., Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS. 
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the 
structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol J 2007;4:23. 
 74 
[112] Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J, et al. Two 
complex, adenovirus-based vaccines that together induce immune responses to all four 
dengue virus serotypes. Clin Vaccine Immunol 2007;14(2):182-9. 
[113] Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper 
systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous 
genes in vitro and immunization against heterologous pathogens in vivo. Virology 
1997;239(2):389-401. 
[114] Grieder FB, Davis NL, Aronson JF, Charles PC, Sellon DC, Suzuki K, et al. Specific 
restrictions in the progression of Venezuelan equine encephalitis virus-induced disease 
resulting from single amino acid changes in the glycoproteins. Virology 1995;206(2):994-
1006. 
[115] Davis NL, Brown KW, Johnston RE. A viral vaccine vector that expresses foreign 
genes in lymph nodes and protects against mucosal challenge. J Virol 1996;70(6):3781-7. 
[116] Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA, et al. 
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus 
type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J 
Virol 1997;71(4):3031-8. 
[117] Johnston RE, Johnson PR, Connell MJ, Montefiori DC, West A, Collier ML, et al. 
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine 
encephalitis virus replicon particle vectors followed by a mucosal challenge with 
SIVsmE660. Vaccine 2005;23(42):4969-79. 
[118] Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS. Systemic, 
mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine 
encephalitis replicons expressing Norwalk virus-like particles. J Virol 2002;76(2):730-42. 
[119] Balasuriya UB, Heidner HW, Davis NL, Wagner HM, Hullinger PJ, Hedges JF, et al. 
Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis 
virus induce high level protection against challenge with virulent virus in vaccinated horses. 
Vaccine 2002;20(11-12):1609-17. 
[120] Chulay J, Burke D, Karim S, Russel N, Wecker M, Allen M, et al. Safety and 
immunogenicity of an alphavirus replicon HIV gag vaccine (AVX101) in helthy HIV-
uninfected adults. Abstracts-Antiviral Therapy 2006;11(Supplement 2):196. 
 75 
[121] White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE. An 
immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes 
maternal antibody interference in weanling mice. J Virol 2007;81(19):10329-39. 
[122] Balasuriya UB, Heidner HW, Hedges JF, Williams JC, Davis NL, Johnston RE, et al. 
Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is 
necessary for induction of neutralizing antibodies in mice immunized with recombinant 
Venezuelan equine encephalitis virus replicon particles. J Virol 2000;74(22):10623-30. 
[123] Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, et al. 
Vaccination of macaques against pathogenic simian immunodeficiency virus with 
Venezuelan equine encephalitis virus replicon particles. J Virol 2000;74(1):371-8. 
[124] Kraus AA, Messer W, Haymore LB, de Silva AM. Comparison of plaque- and flow 
cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 
2007;45(11):3777-80. 
[125] Lambeth CR, White LJ, Johnston RE, de Silva AM. Flow cytometry-based assay for 
titrating dengue virus. J Clin Microbiol 2005;43(7):3267-72. 
[126] Allison SL, Tao YJ, O'Riordain G, Mandl CW, Harrison SC, Heinz FX. Two distinct 
size classes of immature and mature subviral particles from tick-borne encephalitis virus. J 
Virol 2003;77(21):11357-66. 
[127] Sugrue RJ, Fu J, Howe J, Chan YC. Expression of the dengue virus structural proteins 
in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 1997;78 ( Pt 
8):1861-6. 
[128] Courageot MP, Frenkiel MP, Dos Santos CD, Deubel V, Despres P. Alpha-
glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion 
morphogenesis in the endoplasmic reticulum. J Virol 2000;74(1):564-72. 
[129] Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res 2003;59:141-
75. 
[130] Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 
2005;437(7059):764-9. 
 76 
[131] Mason PW, Dalrymple JM, Gentry MK, McCown JM, Hoke CH, Burke DS, et al. 
Molecular characterization of a neutralizing domain of the Japanese encephalitis virus 
structural glycoprotein. J Gen Virol 1989;70 ( Pt 8):2037-49. 
[132] Lin CW, Wu SC. A functional epitope determinant on domain III of the Japanese 
encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J 
Virol 2003;77(4):2600-6. 
 
 
